TY - JOUR A1 - Dempfle, Astrid A1 - Herpertz-Dahlmann, Beate A1 - Timmesfeld, Nina A1 - Schwarte, Reinhild A1 - Egberts, Karin M. A1 - Pfeiffer, Ernst A1 - Fleischhaker, Christian A1 - Wewetzer, Christoph A1 - Bühren, Katharina T1 - Predictors of the resumption of menses in adolescent anorexia nervosa JF - BMC Psychiatry N2 - Background: The resumption of menses is an important indicator of recovery in anorexia nervosa (AN). Patients with early-onset AN are at particularly great risk of suffering from the long-term physical and psychological consequences of persistent gonadal dysfunction. However, the clinical variables that predict the recovery of menstrual function during weight gain in AN remain poorly understood. The aim of this study was to investigate the impact of several clinical parameters on the resumption of menses in first-onset adolescent AN in a large, well-characterized, homogenous sample that was followed-up for 12 months. Methods: A total of 172 female adolescent patients with first-onset AN according to DSM-IV criteria were recruited for inclusion in a randomized, multi-center, German clinical trial. Menstrual status and clinical variables (i.e., premorbid body mass index (BMI), age at onset, duration of illness, duration of hospital treatment, achievement of target weight at discharge, and BMI) were assessed at the time of admission to or discharge from hospital treatment and at a 12-month follow-up. Based on German reference data, we calculated the percentage of expected body weight (%EBW), BMI percentile, and BMI standard deviation score (BMI-SDS) for all time points to investigate the relationship between different weight measurements and resumption of menses. Results: Forty-seven percent of the patients spontaneously began menstruating during the follow-up period. %EBW at the 12-month follow-up was strongly correlated with the resumption of menses. The absence of menarche before admission, a higher premorbid BMI, discharge below target weight, and a longer duration of hospital treatment were the most relevant prognostic factors for continued amenorrhea. Conclusions: The recovery of menstrual function in adolescent patients with AN should be a major treatment goal to prevent severe long-term physical and psychological sequelae. Patients with premenarchal onset of AN are at particular risk for protracted amenorrhea despite weight rehabilitation. Reaching and maintaining a target weight between the 15th and 20th BMI percentile is favorable for the resumption of menses within 12 months. Whether patients with a higher premorbid BMI may benefit from a higher target weight needs to be investigated in further studies. KW - girls KW - amenorrhea KW - brain KW - increases KW - return KW - menarche KW - target weight KW - adolescence anorexia nervosa KW - resumption of menses KW - recovery KW - ovarian function KW - weight gain KW - eating disorders KW - bone-mineral density KW - menstrual recovery KW - outcome KW - body mass index Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-122106 VL - 13 IS - 308 ER - TY - THES A1 - Eckert, Lisa Doreen T1 - Multimodale Verfahren zum Eisenstoffwechsel bei ADHS - Vergleichende Bildgebung T1 - Multimodal methods for iron metabolism in ADHD - Comparative imaging N2 - Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) gehört weltweit zu den bedeutendsten psychiatrischen Erkrankungen des Kinder- und Jugendalters. Die Pathomechanismen sind aktuell noch nicht vollständig geklärt, wobei es deutliche Hinweise auf hirnorganische Veränderungen gibt. Die transkranielle Sonographie stellt eine nicht-invasive Methode dar, strukturelle Unterschiede tiefer Hirnstrukturen zu untersuchen. Bereits in vorangegangenen Studien konnte mit der Methode eine Veränderung der Echogenität der Substantia nigra (SN) bei Kindern mit ADHS im Vergleich zu gesunden Kontrollprobanden nachgewiesen werden. In dieser Studie sollen nun die möglichen physiologischen Hintergründe der erhöhten Echogenität der Substantia Nigra in Zusammenschau mit bildgebenden Verfahren betrachtet werden. Hierzu wurde in der vorliegenden multimodalen Studie bei 20 männlichen Kindern mit ADHS im Alter zwischen 8 und 12 Jahren eine transkranielle Ultraschalluntersuchung (TCS) zur Bestimmung der echogenen Fläche der Substantia Nigra sowie ein neuromelaninsensitives cMRT zur Bestimmung des neuromelaninassoziierten Volumens der SN, sowie des neuromelaninassoziierten Kontrastes SN/Cb durchgeführt. Als Kennwerte des peripheren Eisenhaushalts wurden die Konzentrationen von Eisen, Ferritin und Transferrin im Blut bestimmt. In die Auswertung gingen außerdem die Stärke der ADHS-Symptomatik (Strength and Difficulties Questionaire, SDQ; Fremdbeurteilungsbogen bei ADHS, FBB-ADHS), die kognitive Begabung (über CFT-20-R) und das Alter der Probanden ein. Psychiatrische Komorbidität wurde mit Hilfe der Child Behaviour Checklist (CBCL) erhoben. N2 - Attention deficit/hyperactivity disorder (ADHD) is one of the most important psychiatric diseases of children and adolescents worldwide. The pathomechanisms are currently not yet fully understood, although there are clear indications of organic brain changes. Transcranial sonography is a non-invasive method, to investigate structural differences in deep brain structures. In previous studies, the method was able to demonstrate a change in the echogenicity of the substantia nigra (SN) in children with ADHD compared to healthy control subjects. This study investigates the possible physiological background of the increased echogenicity of the substantia nigra including imaging procedures. For this purpose, in the present multimodal study, a transcranial ultrasound examination (TCS) to determine the echogenic area of the substantia nigra and a neuromelanin-sensitive cMRI to detect the neuromelanin-associated volume of the SN and the neuromelanin-associated Contras SN/Cb were used in 20 male children with ADHD between the ages of 8 and 12 years. The concentrations of iron, ferritin and transferrin in the blood were determined as parameters of the peripheral iron balance. The evaluation also included the strength of the ADHD symptoms (Strength and Difficulties Questionnaire, SDQ; external assessment form for ADHD, FBB-ADHD), the cognitive ability (via CFT-20-R) and the age of the test subjects. Psychiatric comorbidity was assessed using the Child Behavior Checklist (CBCL). KW - TCS KW - Neuromelanin KW - ADHS KW - Transkranielle Sonographie KW - Aufmerksamkeitsdefizit-Syndrom KW - Zweikomponentensystem KW - Eisen Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-348295 ER - TY - JOUR A1 - Egberts, Karin A1 - Fekete, Stefanie A1 - Häge, Alexander A1 - Hiemke, Christoph A1 - Scherf-Clavel, Maike A1 - Taurines, Regina A1 - Unterecker, Stefan A1 - Gerlach, Manfred A1 - Romanos, Marcel T1 - Therapeutisches Drug Monitoring zur Optimierung der Psychopharmakotherapie von Kindern und Jugendlichen: Update und Leitfaden für die Praxis JF - Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie N2 - Trotz verbesserter Evidenzbasis bestehen in der kinder- und jugendpsychiatrischen Pharmakotherapie viele Unsicherheiten über die Wirkung und Verträglichkeit der häufig off-label oder in Kombinationstherapie verordneten Medikamente. Gerade auch vor dem Hintergrund der in vielen Fällen notwendigen mittel- bis langfristigen Einnahme sollen unerwünschte Arzneimittelwirkungen in dieser Altersstufe möglichst minimiert und eine auf die individuellen Charakteristika der Patientin oder des Patienten zugeschnittene, effektive Dosierung gefunden werden. Kinder und Jugendliche scheinen nicht nur besonders anfällig für bestimmte unerwünschte Arzneimittelwirkungen, sondern sind auch iatrogenen Risiken durch Dosierungs- oder Applikationsfehler ausgesetzt, die zu Unter- oder Überdosierungen führen können mit entsprechend negativen Auswirkungen auf den Therapieerfolg. Neben einer strengen Indikationsstellung sind daher eine präzise Dosisfindung sowie systematische Überwachung der Sicherheit der Psychopharmakotherapie unverzichtbar. In diesem Artikel wird Therapeutisches Drug Monitoring als hilfreiches klinisches Instrument vorgestellt und beschrieben, wie dessen richtige Anwendung sowohl die Wirksamkeit als auch die Sicherheit und Verträglichkeit einer Psychopharmakotherapie im Kindes- und Jugendalter zum unmittelbaren Nutzen für die Patientinnen und Patienten verbessern kann. N2 - Despite the improved evidence base, many uncertainties remain in child and adolescent psychiatric pharmacotherapy about the efficacy and tolerability of drugs, which are often prescribed off-label or in combination therapy in this age group. Because medium- to long-term use is unavoidable in many cases, clinicians should minimize adverse drug reactions as far as possible and tailor an effective dosage to the individual characteristics of the patient. Not only are children and adolescents particularly vulnerable to certain adverse drug effects, they are also exposed to iatrogenic risks from dosing or application errors, which can lead to under- or overdosing with correspondingly negative effects on the success of the therapy. In addition to determining a strict indication, it is therefore essential to establish precise dosage and systematic monitoring of the safety of the psychopharmacotherapy. This article introduces therapeutic drug monitoring as a useful clinical tool and describes how its correct application in practice can improve the efficacy as well as the safety and tolerability of psychotropic therapy in children and adolescents for the immediate benefit of patients. T2 - Therapeutic drug monitoring to optimize psychopharmacotherapy in children and adolescents - Update and guidelines for practice KW - Psychopharmakotherapie KW - unerwünschte Arzneimittelwirkungen KW - Pharmakovigilanz KW - Therapeutisches Drug Monitoring KW - Qualitätssicherung KW - psychopharmacotherapy KW - adverse drug reactions KW - pharmacovigilance KW - therapeutic drug monitoring KW - quality assurance Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262038 SN - 1422-4917 SN - 1664-2880 VL - 50 IS - 2 ER - TY - JOUR A1 - Emser, Theresa S. A1 - Johnston, Blair A. A1 - Steele, J. Douglas A1 - Kooij, Sandra A1 - Thorell, Lisa A1 - Christiansen, Hanna T1 - Assessing ADHD symptoms in children and adults: evaluating the role of objective measures JF - Behavioral and Brain Functions N2 - Background: Diagnostic guidelines recommend using a variety of methods to assess and diagnose ADHD. Applying subjective measures always incorporates risks such as informant biases or large differences between ratings obtained from diverse sources. Furthermore, it has been demonstrated that ratings and tests seem to assess somewhat different constructs. The use of objective measures might thus yield valuable information for diagnosing ADHD. This study aims at evaluating the role of objective measures when trying to distinguish between individuals with ADHD and controls. Our sample consisted of children (n = 60) and adults (n = 76) diagnosed with ADHD and matched controls who completed self- and observer ratings as well as objective tasks. Diagnosis was primarily based on clinical interviews. A popular pattern recognition approach, support vector machines, was used to predict the diagnosis. Results: We observed relatively high accuracy of 79% (adults) and 78% (children) applying solely objective measures. Predicting an ADHD diagnosis using both subjective and objective measures exceeded the accuracy of objective measures for both adults (89.5%) and children (86.7%), with the subjective variables proving to be the most relevant. Conclusions: We argue that objective measures are more robust against rater bias and errors inherent in subjective measures and may be more replicable. Considering the high accuracy of objective measures only, we found in our study, we think that they should be incorporated in diagnostic procedures for assessing ADHD. KW - ADHD KW - support vector machines KW - classification KW - objective assessment KW - children/adults Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-175717 VL - 14 IS - 11 ER - TY - THES A1 - Euteneuer, Wolfram T1 - Nierentransplantation an der Universität Würzburg - eine retrospektive Datenanalyse von 1984 bis 2004 T1 - Nephrotransplantation at the University of Würzburg - a retrospective data-analysis from 1984 to 2004 N2 - Am Klinikum der Julius-Maximilians-Universität Würzburg werden seit Dezember 1984 Nierentransplantationen durchgeführt. Die vorliegende Arbeit erfasst retrospektiv den Zeitraum zwischen 1984 und 2004 und versucht, ein Bild von der Entwicklung des Nierentransplantationsprogramms in Würzburg und den erreichten Erfolgen zu vermitteln. Im Laufe dieser Zeit unterlag die Population der Organspender und der Organempfänger einem stetigen Wandel, während sich die eingesetzten immunsuppressiven Schemata häufig veränderten. Viele neue Medikamente wurden im Laufe der Jahre eingeführt und Therapierichtlinien definiert, die zielgenauer das Immunsystem therapeutisch ausschalteten. N2 - This is a retrospective data-analysis of the kidney transplantation program of the university of wuerzburg. From 1984 to 2004 about 560 transplantations were recorded in a data base. KW - Nierentransplantion KW - Transplantation KW - Immunsuppression KW - Transplantatüberleben KW - nephrotransplantation KW - renal KW - transplantation KW - immunosuppression Y1 - 2006 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-20759 ER - TY - JOUR A1 - Farmer, Adam D. A1 - Strzelczyk, Adam A1 - Finisguerra, Alessandra A1 - Gourine, Alexander V. A1 - Gharabaghi, Alireza A1 - Hasan, Alkomiet A1 - Burger, Andreas M. A1 - Jaramillo, Andrés M. A1 - Mertens, Ann A1 - Majid, Arshad A1 - Verkuil, Bart A1 - Badran, Bashar W. A1 - Ventura-Bort, Carlos A1 - Gaul, Charly A1 - Beste, Christian A1 - Warren, Christopher M. A1 - Quintana, Daniel S. A1 - Hämmerer, Dorothea A1 - Freri, Elena A1 - Frangos, Eleni A1 - Tobaldini, Eleonora A1 - Kaniusas, Eugenijus A1 - Rosenow, Felix A1 - Capone, Fioravante A1 - Panetsos, Fivos A1 - Ackland, Gareth L. A1 - Kaithwas, Gaurav A1 - O'Leary, Georgia H. A1 - Genheimer, Hannah A1 - Jacobs, Heidi I. L. A1 - Van Diest, Ilse A1 - Schoenen, Jean A1 - Redgrave, Jessica A1 - Fang, Jiliang A1 - Deuchars, Jim A1 - Széles, Jozsef C. A1 - Thayer, Julian F. A1 - More, Kaushik A1 - Vonck, Kristl A1 - Steenbergen, Laura A1 - Vianna, Lauro C. A1 - McTeague, Lisa M. A1 - Ludwig, Mareike A1 - Veldhuizen, Maria G. A1 - De Couck, Marijke A1 - Casazza, Marina A1 - Keute, Marius A1 - Bikson, Marom A1 - Andreatta, Marta A1 - D'Agostini, Martina A1 - Weymar, Mathias A1 - Betts, Matthew A1 - Prigge, Matthias A1 - Kaess, Michael A1 - Roden, Michael A1 - Thai, Michelle A1 - Schuster, Nathaniel M. A1 - Montano, Nicola A1 - Hansen, Niels A1 - Kroemer, Nils B. A1 - Rong, Peijing A1 - Fischer, Rico A1 - Howland, Robert H. A1 - Sclocco, Roberta A1 - Sellaro, Roberta A1 - Garcia, Ronald G. A1 - Bauer, Sebastian A1 - Gancheva, Sofiya A1 - Stavrakis, Stavros A1 - Kampusch, Stefan A1 - Deuchars, Susan A. A1 - Wehner, Sven A1 - Laborde, Sylvain A1 - Usichenko, Taras A1 - Polak, Thomas A1 - Zaehle, Tino A1 - Borges, Uirassu A1 - Teckentrup, Vanessa A1 - Jandackova, Vera K. A1 - Napadow, Vitaly A1 - Koenig, Julian T1 - International Consensus Based Review and Recommendations for Minimum Reporting Standards in Research on Transcutaneous Vagus Nerve Stimulation (Version 2020) JF - Frontiers in Human Neuroscience N2 - Given its non-invasive nature, there is increasing interest in the use of transcutaneous vagus nerve stimulation (tVNS) across basic, translational and clinical research. Contemporaneously, tVNS can be achieved by stimulating either the auricular branch or the cervical bundle of the vagus nerve, referred to as transcutaneous auricular vagus nerve stimulation(VNS) and transcutaneous cervical VNS, respectively. In order to advance the field in a systematic manner, studies using these technologies need to adequately report sufficient methodological detail to enable comparison of results between studies, replication of studies, as well as enhancing study participant safety. We systematically reviewed the existing tVNS literature to evaluate current reporting practices. Based on this review, and consensus among participating authors, we propose a set of minimal reporting items to guide future tVNS studies. The suggested items address specific technical aspects of the device and stimulation parameters. We also cover general recommendations including inclusion and exclusion criteria for participants, outcome parameters and the detailed reporting of side effects. Furthermore, we review strategies used to identify the optimal stimulation parameters for a given research setting and summarize ongoing developments in animal research with potential implications for the application of tVNS in humans. Finally, we discuss the potential of tVNS in future research as well as the associated challenges across several disciplines in research and clinical practice. KW - transcutaneous vagus nerve stimulation KW - minimum reporting standards KW - guidelines & recommendations KW - transcutaneous auricular vagus nerve stimulation KW - transcutaneous cervical vagus nerve stimulation Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234346 SN - 1662-5161 VL - 14 ER - TY - JOUR A1 - Fauser, Mareike A1 - Weselek, Grit A1 - Hauptmann, Christine A1 - Markert, Franz A1 - Gerlach, Manfred A1 - Hermann, Andreas A1 - Storch, Alexander T1 - Catecholaminergic Innervation of Periventricular Neurogenic Regions of the Developing Mouse Brain JF - Frontiers in Neuroanatomy N2 - The major catecholamines—dopamine (DA) and norepinephrine (NE)—are not only involved in synaptic communication but also act as important trophic factors and might ultimately be involved in mammalian brain development. The catecholaminergic innervation of neurogenic regions of the developing brain and its putative relationship to neurogenesis is thus of pivotal interest. We here determined DA and NE innervation around the ventricular/subventricular zone (VZ/SVZ) bordering the whole ventricular system of the developing mouse brain from embryonic day 14.5 (E14.5), E16.5, and E19.5 until postnatal day zero (P0) by histological evaluation and HPLC with electrochemical detection. We correlated these data with the proliferation capacity of the respective regions by quantification of MCM\(^{2+}\) cells. During development, VZ/SVZ catecholamine levels dramatically increased between E16.5 and P0 with DA levels increasing in forebrain VZ/SVZ bordering the lateral ventricles and NE levels raising in midbrain/hindbrain VZ/SVZ bordering the third ventricle, the aqueduct, and the fourth ventricle. Conversely, proliferating MCM\(^{2+}\) cell counts dropped between E16.5 and E19.5 with a special focus on all VZ/SVZs outside the lateral ventricles. We detected an inverse strong negative correlation of the proliferation capacity in the periventricular neurogenic regions (log-transformed MCM\(^{2+}\) cell counts) with their NE levels (r = −0.932; p < 0.001), but not their DA levels (r = 0.440; p = 0.051) suggesting putative inhibitory effects of NE on cell proliferation within the periventricular regions during mouse brain development. Our data provide the first framework for further demandable studies on the functional importance of catecholamines, particularly NE, in regulating neural stem/progenitor cell proliferation and differentiation during mammalian brain development. KW - brain development KW - ventricular zone KW - catecholamines KW - norepinephrine KW - dopamine KW - neurogenesis Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-212485 VL - 14 ER - TY - THES A1 - Fekete, Stefanie T1 - Therapeutisches Drug Monitoring (TDM) von Kindern und Jugendlichen unter Behandlung mit Tiaprid : eine prospektive naturalistische Beobachtungsstudie T1 - Therapeutic drug monitoring (TDM) of children and adolescents treated with tiapride N2 - Tiaprid wird bei Kindern und Jugendlichen im deutschsprachigen Raum als Mittel der ersten Wahl zur Behandlung von Ticstörungen off-label eingesetzt. Es gilt dabei die generelle Empfehlung, Therapeutischen Drug Monitoring (TDM) bei der Behandlung von Minderjährigen mit Neuro-/Psychopharmaka durchzuführen. Therapeutische Referenzbereiche für Tiaprid sind bisher jedoch nur für erwachsene Patienten mit Chorea Huntington definiert worden (1000 bis 2000 ng/ml) (Hiemke et al., 2011). An ausgewählten Zentren im Rahmen des Kompetenznetzwerks Therapeutisches Drug Monitoring Kinder- und Jugendpsychiatrie (www.tdm-kjp.com) wurden von 2007 bis 2014 standardisiert TDM-Daten erfasst, um den Zusammenhang zwischen Dosis, Serumkonzentration, Wirksamkeit und UAW von Tiaprid zu untersuchen sowie Hinweise auf einen möglichen alters- und diagnosespezifischen therapeutischen Referenzbereich zu generieren. Bei den 49 Patienten (mittleres Alter 12,5 Jahre; 84 % männlich) zeigte sich eine positive Korrelation (r= 0.76; p< .001) zwischen der Dosis (Mittelwert 354 mg) und der Serumkonzentration von Tiaprid (Mittelwert 1324 ng/ml) mit einer ausgeprägten interindividuellen Variabilität, jedoch keine Beziehung zwischen Serumkonzentration und Wirkeffekt (83,3 % profitierten) bzw. UAW in der Gesamtpopulation. Die Auswertung der Verlaufsmessungen von Patienten mit mehreren Messungen der Tiaprid-Serumkonzentration ergab beim dritten Messzeitpunkt eine negative Korrelation zwischen Wirkeffekt und Serumkonzentration (r= -.68; p= .032). Bei Patienten mit Serumkonzentrationen unter 2000 ng/ml wurde ein günstigerer klinischer Effekt dokumentiert als bei solchen mit Konzentrationen oberhalb dieses Wertes. Die ROC-Analyse ergab eine Sensitivität von 86 %, ab einer Konzentration von 618 ng/ml zu respondieren (AUC= .524). Kein Patient litt an einer schweren UAW und nur wenige Patienten unter leichten oder mittelschweren UAW (n=13). Diese Ergebnisse lassen vermuten, dass der untere therapeutische Referenzbereich für jugendliche Patienten mit einer Tic-Störung bei etwa 600 ng/ml liegt und die obere Grenze von 2000 ng/ml auch als Orientierungswert auf Kinder und Jugendliche gelten könnte. Bevor diesbezüglich gültige Empfehlungen für den klinischen Alltag formuliert werden, müssen Studien mit höheren Fallzahlen und mehr kontrollierten Studiendesigns abgewartet werden.  N2 - Background: Tiapride is used off-label as first-line treatment for children and adolescents with tic disorders in German speaking countries. Methods: Standardized TDM data were collected from 2007 to 2014 within the Competence Network Therapeutic Drug Monitoring in Child and Adolescent Psychiatry (www.tdm-kjp.com) to investigate the correlation between dosage, serum concentration, effectiveness and adverse drug reactions (ADRs) of tiapride. Additionally, information about a possible age- and diagnosis-specific therapeutic reference range should be obtained as the therapeutic reference ranges for tiapride are only available for adult patients with chorea Huntington (1000 to 2000 ng/ml). Results: In the 49 paediatric patients (mean age = 12.5 years, 84% male), a positive correlation (r = 0.76; p <.001) was found between tiapride dose (mean = 353.6 mg) and serum concentration (mean = 1324.0 ng/ml) with marked interindividual variability, but no relationship between serum concentration and effect (83.3% profit) nor ADRs. No patient suffered from severe ADRs and only a few patients had mild or moderate ADRs (n = 13). The evaluation of the measurements of patients with multiple measurements of the tiapride serum concentration (N = 10) showed a negative correlation between effect and serum concentration after one year treatment with tiapride (r = -.68, p = .032). A better outcome in patients with serum concentrations below 2000 ng / ml was observed. ROC analysis revealed a sensitivity of 86% from a concentration of 618 ng/ml in regard to the therapeutic response. Discussion: These results suggest that the lower therapeutic reference range in adolescent patients with tic disorders could be about 600 ng/ml and the upper limit of the adult therapeutic reference range of 2000 ng/ml could be a reference point as a guide to children and adolescents in terms of the incidence of ADRs and the expected effect. KW - therapeutic drug monitoring KW - paediatrics KW - tiapride KW - tic disorders KW - children Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173085 ER - TY - JOUR A1 - Fekete, Stefanie A1 - Egberts, K. A1 - Preissler, T. A1 - Wewetzer, C. A1 - Mehler-Wex, C. A1 - Romanos, M. A1 - Gerlach, M. T1 - Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride JF - European Journal of Clinical Pharmacology N2 - Purpose Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated. Methods Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures. Results In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg/kg, range 0.97–19.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs. Conclusions This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng/ml) and similar upper limit (2000 ng/ml). KW - Tourette syndrome KW - therapeutic drug monitoring KW - serum concentration KW - paediatrics KW - pharmacokinetics Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-279893 VL - 77 IS - 2 ER - TY - GEN A1 - Fekete, Stefanie A1 - Egberts, K. A1 - Preissler, T. A1 - Wewetzer, C. A1 - Mehler-Wex, C. A1 - Romanos, M. A1 - Gerlach, M. T1 - Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride T2 - European Journal of Clinical Pharmacology N2 - Correction to: European Journal of Clinical Pharmacology (2021) 77:163–170 https://doi.org/10.1007/s00228-020-03000-0 KW - Erratum Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-329467 VL - 77 IS - 8 ER - TY - JOUR A1 - Fekete, Stefanie A1 - Kulpok, Christine A1 - Taurines, Regina A1 - Egberts, Karin A1 - Geissler, Julia A1 - Gerlach, Manfred A1 - Malonga Makosi, Dorothée A1 - König, Jochem A1 - Urschitz, Michael S. A1 - Toni, Irmgard A1 - Neubert, Antje A1 - Romanos, Marcel T1 - Value of a web-based pediatric drug information system to prevent serious adverse drug reactions in child and adolescent psychiatry JF - Journal of Neural Transmission N2 - Psychotropic drugs are frequently prescribed ‘off-label’ to children and adolescents and carry the risk of serious adverse drug reactions (sADR). We examined the frequency of sADRs of psychotropic drugs in pediatric inpatients and explored their potential preventability through following the recommendations of a web-based pediatric drug information system (PDIS). The potential socio-economic impacts of using this online system is also addressed. Routine clinical data from all inpatients treated in a child and adolescent psychiatry department between January 2017 and December 2018 were retrospectively examined for the occurrence of sADRs as defined by the European Medicines Agency. The preventability of the sADRs was assessed based on the information of the PDIS. Furthermore, the expected prolongation of the hospital stay due to sADRs was calculated as well as the associated treatment costs. The study was supported by the Innovation Fund of the Joint Federal Committee, grant number 01NVF16021. In total, 1036 patients were screened of whom 658 (63.5%) received psychopharmacological treatment. In 53 (8.1%) of these patients 54 sADRs were documented, of which 37 sADRs were identified as potentially preventable through PDIS. Mitigating sADR through PDIS would likely have prevented prolonged hospital stays and conferred considerable savings for health insurance companies. PDIS provides systematic and evidence-based information about pediatric psychopharmacotherapy and helps to prevent prescribing errors. Therefore, PDIS is a useful tool to increase drug therapy safety in child and adolescent psychiatry. Further prospective studies are needed to confirm the results. KW - adverse effects KW - pharmacovigilance KW - drug safety KW - psychotropic drugs KW - mental health Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324817 VL - 130 IS - 1 ER - TY - JOUR A1 - Franke, Maximilian A1 - Conzelmann, Annette A1 - Grünblatt, Edna A1 - Werling, Anna M. A1 - Spieles, Helen A1 - Wewetzer, Christoph A1 - Warnke, Andreas A1 - Romanos, Marcel A1 - Walitza, Susanne A1 - Renner, Tobias J. T1 - No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents JF - Frontiers in Molecular Neuroscience N2 - Obsessive-compulsive disorder (OCD) causes severe distress and is therefore counted by the World Health Organisation (WHO) as one of the 10 most impairing illnesses. There is evidence for a strong genetic underpinning especially in early onset OCD (eoOCD). Though several genes involved in neurotransmission have been reported as candidates, there is still a need to identify new pathways. In this study, we focussed on genetic variants of the Neuropeptide Y (NPY) system. NPY is one of the most abundant neuropeptides in the human brain with emerging evidence of capacity to modulate stress response, which is of high relevance in OCD. We focussed on tag-SNPs of NPY and its receptor gene NPY1R in a family-based approach. The sample comprised 86 patients (children and adolescents) with eoOCD with both their biological parents. However, this first study on genetic variants of the NPY-system could not confirm the association between the investigated SNPs and eoOCD. Based on the small sample size results have to be interpreted as preliminary and should be replicated in larger samples. However, also in an additional GWAS analysis in a large sample, we could not observe an associations between NPY and OCD. Overall, these preliminary results point to a minor role of NPY on the stress response of OCD. KW - NPY KW - obsessive-compulsive KW - children KW - anxiety KW - neuropeptide Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229051 VL - 12 ER - TY - THES A1 - Frey, Lillien Mara T1 - Furchtgeneralisierung und Attentional Bias bei Kindern und Jugendlichen mit einer Störung des Sozialverhaltens T1 - Fear Generalization And Attentional Bias in Children And Adolescents With Conduct Disorder N2 - Bereits vorangegangene Studien haben zeigen können, dass eine verstärke Generali- sierung von Furcht sowohl bei Erwachsenen, bei denen beispielsweise eine Angststörung oder eine PTSB diagnostiziert wurde, aber auch bei gesunden Kindern eine Rolle spielt. In unserer Studie untersuchten wir eine Gruppe Kinder und Jugendliche (n = 31, m = 25, w = 6; Alter = 13.35 ± 2.03), die eine Störung des Sozialverhaltens aufwiesen, auf die Konditionierbarkeit von Furcht und eine mögliche Furchtgeneralisierung. Diese Gruppe verglichen wir mit einer gesunden Kontrollgruppe (n = 29, m = 11, w = 18; Alter = 14.28 ± 2.43). Als Generalisierungsstimuli verwendeten wir ein Furchtgeneralisierungsparadigma mit zwei Frauengesichtern, die in vier Schritten aneinander angeglichen wurden. Zusätzlich führten wir mit beiden Probandengruppen ein Dot-Probe-Paradigma zur Objektivierung von Aufmerksamkeitsprozessen im Sinne eines Attentional Bias oder Attentional Avoidance mit emotionalen Gesichtern durch. Wir konnten eine erfolgreiche Furchtkonditionierung für beide Gruppen erreichen. Im Vergleich mit der gesunden Kontrollgruppe zeigte die externalisierende Probandengruppe eine verstärke Furchtgeneralisierung. Hinsichtlich der subjektiven Valenz- und Kontingenzratings wurden die Unterschiede besonders deutlich. Eine verstärkte Generalisierungsneigung bei erhöhter Trait-Angst konnten wir nicht finden. Die externalisierende Gruppe zeigte im Vergleich mit neutralen Gesichtern bei den emotionalen Gesichtern insgesamt einen Attentional Bias. Am deutlichsten war dabei eine verstärkte Aufmerksamkeitslenkung hin zu glücklichen Gesichtern festzustellen. Für die gesunde Kontrollgruppe konnten wir keine Besonderheiten bezüglich der Aufmerksamkeitsrichtung finden. Weiterführende Studien sollten mit größ- eren Probandengruppen und nach Geschlecht und Alter gepaarten Probanden durch- geführt werden. Mit externalisierenden Probanden sollte ein Furchtgeneralisierungs- paradigma mit neutralen Stimuli (z.B. Ringe) gewählt werden, um eine subjektive Wertung emotionaler Gesichter bei den Ratings als Störfaktor auszuschließen. Für externalisierende Probanden sollte außerdem die Ausprägung von CU-Traits erfasst und die Dauer der Testung verkürzt oder auf zwei Termine aufgeteilt werden, um eine ausreichende Konzentrationsfähigkeit zu ermöglichen. N2 - Previous studies have already been able to show that increased generalization of fear plays a role both in adults diagnosed with anxiety disorder or PTSD, but also in healthy children. In our study we examined a group of children and adolescents (n = 31, m = 25, f = 6; age = 13.35 ± 2.03) with conduct disorder for possible fear conditioning and overgeneralization of fear. We compared this group with a healthy control group (n = 29, m = 11, f = 18; age = 14.28 ± 2.43). As generalization stimuli we used a fear generalization paradigm with two female faces that were matched in four steps. In addition both groups performed a dot-probe task to objectify attentional processes in terms of attentional bias or attentional avoidance with emotional faces. We were able to achieve successful fear conditioning for both groups. Compared with the healthy control group the externalizing subject group showed increased fear generalization. Regarding the subjective valence and contingency ratings the differences were particularly evident. We could not find an increased generalization tendency for subjects with increased trait anxiety. The externalizing group showed an attentional bias towards emotional faces compared to neutral faces. Most clearly there was an increased attentional bias towards happy faces. For the healthy control group we could not find any particularities regarding attentional bias or avoidance. Further studies should be conducted with larger subject groups and subjects paired by gender and age. With externalizing subjects a fear-generalization paradigm with neutral stimuli (e.g., rings) should be chosen to exclude subjective scoring of emotional faces in the ratings as a confounding factor. For externalizing subjects, the expression of CU traits should also be recorded and the duration of testing should be shortened or divided into two sessions to enable sufficient concentration. KW - Psychische Störung KW - Kind KW - Furchtgeneralisierung KW - Attentional Bias KW - Attentional Avoidance KW - Störung des Sozialverhaltens KW - Verhaltensstörung KW - Jugend KW - Sekundärkrankheit KW - Angststörung Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259746 ER - TY - JOUR A1 - Föcker, Manuel A1 - Timmesfeld, Nina A1 - Bühlmeier, Judith A1 - Zwanziger, Denise A1 - Führer, Dagmar A1 - Grasemann, Corinna A1 - Ehrlich, Stefan A1 - Egberts, Karin A1 - Fleischhaker, Christian A1 - Wewetzer, Christoph A1 - Wessing, Ida A1 - Seitz, Jochen A1 - Herpertz-Dahlmann, Beate A1 - Hebebrand, Johannes A1 - Libuda, Lars T1 - Vitamin D level trajectories of adolescent patients with anorexia nervosa at inpatient admission, during treatment, and at one year follow up: association with depressive symptoms JF - Nutrients N2 - (1) Background: Evidence has accumulated that patients with anorexia nervosa (AN) are at higher risk for vitamin D deficiency than healthy controls. In epidemiologic studies, low 25(OH) vitamin D (25(OH)D) levels were associated with depression. This study analyzed the relationship between 25(OH)D serum levels in adolescent patients and AN and depressive symptoms over the course of treatment. (2) Methods: 25(OH)D levels and depressive symptoms were analyzed in 93 adolescent (in-)patients with AN from the Anorexia Nervosa Day patient versus Inpatient (ANDI) multicenter trial at clinic admission, discharge, and 1 year follow up. Mixed regression models were used to analyze the relationship between 25(OH)D levels and depressive symptoms assessed by the Beck Depression Inventory (BDI-II). (3) Results: Although mean 25(OH)D levels constantly remained in recommended ranges (≥50 nmol/L) during AN treatment, levels decreased from (in)patient admission to 1 year follow up. Levels of 25(OH)D were neither cross-sectionally, prospectively, nor longitudinally associated with the BDI-II score. (4) Conclusions: This study did not confirm that 25(OH)D levels are associated with depressive symptoms in patients with AN. However, increasing risks of vitamin D deficiency over the course of AN treatment indicate that clinicians should monitor 25(OH)D levels. KW - vitamin D KW - supplements KW - anorexia nervosa KW - depressive symptoms KW - adolescents Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-242662 SN - 2072-6643 VL - 13 IS - 7 ER - TY - JOUR A1 - Geissler, Julia A1 - Jans, Thomas A1 - Banaschewski, Tobias A1 - Becker, Katja A1 - Renner, Tobias A1 - Brandeis, Daniel A1 - Döpfner, Manfred A1 - Dose, Christina A1 - Hautmann, Christopher A1 - Holtmann, Martin A1 - Jenkner, Carolin A1 - Millenet, Sabina A1 - Romanos, Marcel T1 - Individualised short-term therapy for adolescents impaired by attention-deficit/hyperactivity disorder despite previous routine care treatment (ESCAadol)-Study protocol of a randomised controlled trial within the consortium ESCAlife JF - Trials N2 - Background: Despite the high persistence rate of attention-deficit/hyperactivity disorder (ADHD) throughout the lifespan, there is a considerable gap in knowledge regarding effective treatment strategies for adolescents with ADHD. This group in particular often shows substantial psychosocial impairment, low compliance and insufficient response to psychopharmacological interventions. Effective and feasible treatments should further consider the developmental shift in ADHD symptoms, comorbidity and psychosocial adversity as well as family dysfunction. Thus, individualised interventions for adolescent ADHD should comprise a multimodal treatment strategy. The randomised controlled ESCAadol study addresses the needs of this patient group and compares the outcome of short-term cognitive behavioural therapy with parent-based telephone-assisted self-help. Methods/design: In step 1, 160 adolescents aged 12 to 17 years with a diagnosis of ADHD will undergo a treatment as usual (TAU) observation phase of 1 month. In step 2, those still severely affected are randomised to the intervention group with an Individualised Modular Treatment Programme (IMTP) or a telephone-assisted self-help programme for parents (TASH) as an active control condition. The IMTP was specifically designed for the needs of adolescent ADHD. It comprises 10 sessions of individual cognitive behavioural therapy with the adolescents and/or the parents, for which participants choose three out of 10 available focus modules (e.g. organisational skills and planning, emotion regulation, problem solving and stress management, dysfunctional family communication). TASH combines a bibliotherapeutic component with 10 counselling sessions for the parents via telephone. Primary outcome is the change in ADHD symptoms in a clinician-rated diagnostic interview. Outcomes are assessed at inclusion into the study, after the TAU phase, after the intervention phase and after a further 12-week follow-up period. The primary statistical analysis will be by intention-to-treat, using linear regression models. Additionally, we will analyse psychometric and biological predictors and moderators of treatment response. Discussion: ESCAadol compares two short-term non-pharmacological interventions as cost-efficient and feasible treatment options for adolescent ADHD, addressing the specific needs and obstacles to treatment success in this group. We aim to contribute to personalised medicine for adolescent ADHD intended to be implemented in routine clinical care. KW - ADHD KW - adolescents KW - attention-deficit/hyperactivity disorder KW - behaviour therapy KW - RCT KW - individualised modular treatment programme KW - telephone-assisted self-help Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176061 VL - 19 IS - 254 ER - TY - JOUR A1 - Geissler, Julia M. A1 - Werner, Elisabeth A1 - Dworschak, Wolfgang A1 - Romanos, Marcel A1 - Ratz, Christoph T1 - German Law Reform Does Not Reduce the Prevalence of Coercive Measures in Residential Institutions for Children, Adolescents, and Young Adults With Intellectual and Developmental Disabilities JF - Frontiers in Psychiatry N2 - Background: Approximately 10% of children, adolescents and young adults with an intellectual and developmental disability (IDD) in Bavaria live in residential institutions. 2015 saw media reports raising suspicions about excessive use of coercive measures (cM) in those institutions. Until a law reform at the end of 2017 made permission from family courts mandatory for cM, their use was governed by parental consent. The REDUGIA project conducted a representative survey comparing cM and their relation to challenging behaviour (cB) and employee stress in Bavaria pre and post reform. Methods: We sent questionnaires to 65 residential institutions for children, adolescents and young adults with IDD in 2017 (pre reform, T1) and 2019 (post reform, T2). To assess changes, we analysed data from all available questionnaire pairs (T1 and T2, N = 43). We calculated paired t-test and correlative analyses concerning the relationship between cB, cM, and employee stress. Results: The number of residents overall (T1: N = 1,661; T2: N = 1,673) and per institution (T1: m = 38.6 ± 32.0; T2: m = 38.9 ± 34.5, p = 0.920) remained stable. We did not see any changes in the Index cB (p = 0.508) or the proportion of residents per institution displaying various types of challenging behaviour (all ps>0.220). There was no change in the Index cM (p = 0.089) or any indicator of employee stress, all ps > 0.323. At follow-up, the Index cB correlated positively with the Index cM (r = 0.519 p < 0.001). Regarding employee stress, the Index cB correlated positively with the frequency of sick leave (r = 0.322, p = 0.037) and physical attacks on employees (r = 0.552, p < 0.001). The Index cM also correlated positively with the frequency of sick leave (r = 0.340, p = 0.028) and physical attacks on employees (r = 0.492, p = 0.001). Discussion: Coercive measures are not a general phenomenon, but are focused on specialised institutions. The law reform did not lead to changes in the number of children, adolescents and young adults with IDD affected by coercive measures in residential institutions in Bavaria. There were still large discrepancies between institutions in the prevalence of challenging behaviour and coercive measures. Coercive measures were associated with challenging behaviour and employee stress. Taken together, findings from REDUGIA emphasise the need to prevent challenging behaviour and thus coercive measures. KW - intellectual disabilities KW - developmental disabilities KW - challenging behaviours KW - employee stress KW - coercive measures KW - residential institutions Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-249030 SN - 1664-0640 VL - 12 ER - TY - JOUR A1 - Geissler, Julia A1 - Werner, Elisabeth A1 - Dworschak, Wolfgang A1 - Romanos, Marcel A1 - Ratz, Christoph T1 - Freiheitsentziehende Maßnahmen in bayerischen Heimeinrichtungen für Kinder, Jugendliche und junge Volljährige mit Intelligenzminderung JF - Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie N2 - Fragestellung: In Bayern leben etwa 10 % aller jungen Menschen mit Intelligenzminderung in Heimeinrichtungen. 2016 wurde in Presseberichten der Vorwurf unzulässiger freiheitsentziehender Maßnahmen formuliert. Im Rahmen des Projekts REDUGIA wurde in bayerischen Heimeinrichtungen eine repräsentative Erhebung zu freiheitsentziehenden Maßnahmen (FeM), herausforderndem Verhalten (hfV) und der Mitarbeiterbelastung (MaB) durchgeführt. Methodik: 65 Einrichtungen für junge Menschen mit Intelligenzminderung in Bayern wurde ein Fragebogen zu strukturellen Gegebenheiten sowie MaB, hfV und FeM zugesendet. Neben deskriptiven Auswertungen wurden korrelative Analysen bzw. Regressionsanalysen zum Zusammenhang zwischen hfV, FeM und MaB durchgeführt. Ergebnisse: Es wurden Daten zu 1839 Personen in 61 Einrichtungen erhoben. 84.3 % der Einrichtungen berichteten geringe Raten an hfV und FeM, während 15.7 % ein gehäuftes Vorkommen von hfV und FeM angaben. Auf n = 1809 Vollzeitäquivalente kam es innerhalb von 14 Tagen zu 639 körperlichen Angriffen durch Bewohner_innen. In 12 Monaten wurden problemverhaltensassoziiert 85 Krankmeldungen sowie 33 Versetzungsanträge/Kündigungen berichtet. Es zeigte sich ein signifikant positiver Zusammenhang zwischen hfV und FeM (R² = .307, F = 21.719, p < .001). Die Mitarbeiterbelastung korrelierte positiv mit hfV (r = .507, p < .001). Schlussfolgerungen: Die Studienbefunde weisen darauf hin, dass hfV sowie FeM bei jungen Menschen mit Intelligenzminderung kein flächendeckendes Phänomen darstellen, sondern sich auf wenige spezialisierte Einrichtungen fokussieren. Mögliche Maßnahmen zur Prävention von Problemverhalten und Freiheitsentzug werden diskutiert. N2 - Objective: In Bavaria, around 10 % of youths with an intellectual disability (ID) live in residential facilities. In 2015, media raised accusations of inadmissible use of coercive measures. The REDUGIA project carried out a representative survey in Bavarian facilities regarding coercive measures (FeM), challenging behavior (hfV), and employee stress (MaB). Method: We sent a questionnaire concerning structural conditions, MaB, hfV and FeM to 65 Bavarian facilities for young people with ID. In addition to preparing descriptive evaluations, we performed correlative and regression analyses concerning the relationship between hfV, FeM, and MaB. Results: We retrieved data from 1,839 subjects in 61 facilities. 84.3 % of facilities reported low rates of hfV and FeM, while 15.7 % reported an increased incidence of hfV and FeM. For n = 1809 full-time position equivalents there were 639 physical attacks by residents over the course of 14 days. We observed 85 instances of sick leave and 33 transfer apllications/resignation associated with hfV. The frequency of hfV predicted the frequency of FeM (R² = 0.307, F = 21.719, p < .001). MaB correlated positively with hfV (r = 0.507, p < .001). Conclusions: The descriptive data indicate that hfV and FeM are not general phenomena but occur mainly in a circumscript number of highly specialized facilities. This emphasizes the need for prevention of hfV and FeM. T2 - Freedom-restricting measures in Bavarian residential facilities for children, adolescents, and young adults with intellectual disabilities KW - Geistige Behinderung KW - herausforderndes Verhalten KW - freiheitsentziehende Maßnahmen KW - Heimeinrichtungen KW - Mitarbeiterbelastung KW - intellectual disability KW - challenging behavior KW - coercive measures KW - residential institutions KW - employee stress Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-244859 SN - 1422-4917 SN - 1664-2880 VL - 49 IS - 4 ER - TY - JOUR A1 - Gerlach, Manfred A1 - Maetzler, Walter A1 - Broich, Karl A1 - Hampel, Harald A1 - Rems, Lucas A1 - Reum, Torsten A1 - Riederer, Peter A1 - Stäffler, Albrecht A1 - Streffer, Johannes A1 - Berg, Daniela T1 - Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics JF - Journal of Neural Transmission N2 - Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies. KW - disease progression KW - biomarkers KW - neuroprotection KW - disease-modifying therapies KW - Parkinson’s disease KW - surrogate endpoints KW - drug development Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125375 VL - 119 IS - 1 ER - TY - JOUR A1 - Gerlach, Manfred A1 - Maetzler, Walter A1 - Broich, Karl A1 - Hampel, Harald A1 - Rems, Lucas A1 - Reum, Torsten A1 - Riederer, Peter A1 - Stöffler, Albrecht A1 - Streffer, Johannes A1 - Berg, Daniela T1 - Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics JF - Journal of Neural Transmission N2 - Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies. KW - Parkinson’s disease KW - Disease-modifying therapies KW - Neuroprotection KW - Biomarkers KW - Surrogate endpoints KW - Drug development KW - Disease progression Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133856 VL - 119 IS - 1 ER - TY - THES A1 - Gernert [geb. Baranski], Stefanie T1 - Assoziationsuntersuchung zu Neuropeptid Y-Polymorphismen bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung T1 - Association between neuropeptide Y-polymorphims and the attention-deficit/hyperactivity disorder in children and adolescens N2 - Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung ist eine der häufigsten psychiatrischen Erkrankung des Kindesalters, die eine hohe Heritabilität aufweist und häufig bis ins Erwachsenenalter persistiert und lebenslang zu sozialen, gesundheitlichen und ökonomischen Problemen führt. Die ADHS tritt bei vielen Patienten in Kombina-tion mit anderen psychiatrischen und nicht-psychiatrischen Erkrankungen auf. In den letzten Jahren rückte zunehmend die häufig zur ADHS komorbid auftretende Adipositas in den Fokus der Forschung. Auf der Suche nach copy number variations in Zusammenhang mit ADHS, wurde eine Duplikation auf Chromosom 7p15 – dem Genlocus des NPY – entdeckt. NPY, ist ein endogenes orexigenes Peptid, welches physiologischerweise die Nahrungsaufnahme stimuliert und neben zahlreichen Effekten, wie Blutdruck- und Knochenregulation, auch in Zusammenhang mit neuropsychiatrischen Erkrankungen gebracht werden konnte. Diese Duplikation auf einem Genort, dessen Produkt für die Regulation von Energiehaushalt und Körpergewicht zuständig ist, bildete die Grundlage, eine Assoziationsuntersuchung zu NPY-Genvarianten und dem Körpergewicht bei Kindern durchzuführen. Untersucht wurden bei 269 an ADHS erkrankten Kindern und 142 gesunden Kontrollkindern die Assoziation zwischen NPY-Genvarianten (rs16147, rs16139, rs5574, rs16124) und ADHS, sowie die Assoziation zwischen NPY-Genvarianten und BMI-Perzentilen bei ADHS. Es ergab sich keine signifikante Assoziation bezüglich der aufgestellten Hypothesen. N2 - The attention-deficit/hyperactivity disorder (ADHD) is one of the most frequent psychiatric disorders in children. It is highly heritable, often persists until adulthood and causes social, economic and health problems. While psychiatric comorbidities of ADHD have been extensively explored, in the last decade mounting evidence pointed to a possible association between ADHD and obesity. In search of copy number variations related to ADHD and this new comorbidity, a duplication on chromosome 7p15 – the gene of Neuropeptide Y (NPY) - has been identified. NPY is an orexigenic peptide, which stimulates food intake and it has also been implicated in other psychiatric diseases. Therefor we performed an association study in a case contol study design including 269 children with ADHD and 142 healthy controls. The objectiv of our investigation was to study the association between four single nucleotid polymorphisms of the NPY- gene (rs16147, rs16139, rs5574, rs16124) and ADHD, and the association between the NPY-polymorphisms and the bmi-percentiles in children with ADHD. Results: No association between the polymorphisms and ADHD in children was found. No association between bmi-percentiles and the polymorphisms was found in children with ADHD. KW - Übergewicht KW - Neuropeptid Y KW - Aufmerksamkeitsdefizit-Syndrom KW - SNP KW - ADHS KW - Kinder und Jugendliche Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-155692 ER - TY - JOUR A1 - Gottschalk, Michael G. A1 - Richter, Jan A1 - Ziegler, Christiane A1 - Schiele, Miriam A. A1 - Mann, Julia A1 - Geiger, Maximilian J. A1 - Schartner, Christoph A1 - Homola, György A. A1 - Alpers, Georg W. A1 - Büchel, Christian A1 - Fehm, Lydia A1 - Fydrich, Thomas A1 - Gerlach, Alexander L. A1 - Gloster, Andrew T. A1 - Helbig-Lang, Sylvia A1 - Kalisch, Raffael A1 - Kircher, Tilo A1 - Lang, Thomas A1 - Lonsdorf, Tina B. A1 - Pané-Farré, Christiane A. A1 - Ströhle, Andreas A1 - Weber, Heike A1 - Zwanzger, Peter A1 - Arolt, Volker A1 - Romanos, Marcel A1 - Wittchen, Hans-Ulrich A1 - Hamm, Alfons A1 - Pauli, Paul A1 - Reif, Andreas A1 - Deckert, Jürgen A1 - Neufang, Susanne A1 - Höfler, Michael A1 - Domschke, Katharina T1 - Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes JF - Translational Psychiatry N2 - Preclinical studies point to a pivotal role of the orexin 1 (OX1) receptor in arousal and fear learning and therefore suggest the HCRTR1 gene as a prime candidate in panic disorder (PD) with/without agoraphobia (AG), PD/AG treatment response, and PD/AG-related intermediate phenotypes. Here, a multilevel approach was applied to test the non-synonymous HCRTR1 C/T Ile408Val gene variant (rs2271933) for association with PD/AG in two independent case-control samples (total n = 613 cases, 1839 healthy subjects), as an outcome predictor of a six-weeks exposure-based cognitive behavioral therapy (CBT) in PD/AG patients (n = 189), as well as with respect to agoraphobic cognitions (ACQ) (n = 483 patients, n = 2382 healthy subjects), fMRI alerting network activation in healthy subjects (n = 94), and a behavioral avoidance task in PD/AG pre- and post-CBT (n = 271). The HCRTR1 rs2271933 T allele was associated with PD/AG in both samples independently, and in their meta-analysis (p = 4.2 × 10−7), particularly in the female subsample (p = 9.8 × 10−9). T allele carriers displayed a significantly poorer CBT outcome (e.g., Hamilton anxiety rating scale: p = 7.5 × 10−4). The T allele count was linked to higher ACQ sores in PD/AG and healthy subjects, decreased inferior frontal gyrus and increased locus coeruleus activation in the alerting network. Finally, the T allele count was associated with increased pre-CBT exposure avoidance and autonomic arousal as well as decreased post-CBT improvement. In sum, the present results provide converging evidence for an involvement of HCRTR1 gene variation in the etiology of PD/AG and PD/AG-related traits as well as treatment response to CBT, supporting future therapeutic approaches targeting the orexin-related arousal system. KW - human behaviour KW - molecular neuroscience KW - personalized medicine KW - predictive markers KW - psychiatric disorders Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227479 VL - 9 ER - TY - THES A1 - Gräfe, Catherin T1 - Familienuntersuchung bei Kindern und Jugendlichen mit ADHS - Unterschiede der DSM-IV Subtypen bezüglich Komorbidität, familiärer Belastung und Krankheitsbeginn T1 - Family-Investigation of Children and Adolescent with ADHD - Differences between DSM-IV Subtypes with regard to Comorbidity, Family History and Age of Onset N2 - Im Rahmen der vorliegenden Arbeit wurden Unterschiede zwischen dem vorwiegend unaufmerksamen und dem kombinierten Subtyp nach DSM-IV anhand von Familien, in denen mindestens zwei Kinder von ADHS betroffen sind, untersucht. Die familiäre Betroffenheit, Art und Anzahl der komorbiden Störungen sowie der Diagnosezeitpunkt wurden bezüglich der Unterschiede zwischen den Subtypen analysiert. Weiterhin wurden epidemiologische und soziodemographische Merkmale beschrieben. Methodik: Im Rahmen einer Multicenterstudie wurden 250 Kinder sowie deren Eltern aus 116 Familien untersucht. ADHS und Komorbiditäten wurden anhand des K-SADS-PL und DIKJ erhoben. Bei den Eltern wurde ADHS anhand der Wender-Utah-Rating-Scale (WURS) und der Barkley-Skalen ermittelt. Ergebnisse: Bei 39% der an ADHS erkrankten Kinder und Jugendlichen lag zusätzlich mindestens eine komorbide Störung zum Zeitpunkt der Untersuchung vor. Die Annahme, dass der kombinierte Subtyp mit einer höheren familiären Belastung einhergeht, konnte im Rahmen der Studie nicht bestätigt werden. Verglichen mit den einfachen Subtypen zeigte sich keine stärkere Betroffenheit von Komorbiditäten beim kombinierten Subtyp. Patienten, die vom kombinierten Subtyp betroffen waren, hatten signifikant häufiger komorbide externalisierende Störungen als Patienten, bei denen ein einfacher Subtyp diagnostiziert worden war. Diese Studie bestätigte die Annahme, dass Patienten, bei denen ein unaufmerksamer Subtyp diagnostiziert worden war, signifikant häufiger an komorbiden internalisierenden Störungen litten und sich verglichen mit den anderen Subtypen durch einen späteren Diagnosezeitpunkt auszeichneten. N2 - The aim of this examination was to examine differences between the combined subtype and the inattentive subtype of ADHD in families with affected siblings. Prevalence of ADHD in parents, comorbidity and age of onset were investigated. Epidemiological data and demographic data were analysed. Method: 250 siblings and parents in 116 families were explored within a multicenterstudy. ADHD and comorbidity were evaluated with K-SADS-PL and DIKJ. Parental ADHD was explored with Wender-Utah-Rating Scale (WURS) and Barkley-Skales. Results: 39% of the children with ADHD had at least one additional comorbid diagnose. Parents of children with a combined subtype did not have higher rates of ADHD. The rate of externalizing disorders was significantly higher in children with a combined subtype. Children with an inattentive subtype were examined to have more internalizing comorbidities and an earlier age of onset. KW - ADHS KW - ADHS KW - Familienuntersuchung KW - DSM-IV Subtyp KW - Komorbiditäten KW - ADHD KW - Family-Investigation KW - DSM-IV Subtype KW - Comorbidity Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-57370 ER - TY - JOUR A1 - Grünblatt, Edna A1 - Oneda, Beatrice A1 - Ekici, Arif B. A1 - Ball, Juliane A1 - Geissler, Julia A1 - Uebe, Steffen A1 - Romanos, Marcel A1 - Rauch, Anita A1 - Walitza, Susanne T1 - High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder JF - BMC Medical Genomics N2 - Background Obsessive-Compulsive Disorder (OCD) is a common and chronic disorder in which a person has uncontrollable, reoccurring thoughts and behaviours. It is a complex genetic condition and, in case of early onset (EO), the patients manifest a more severe phenotype, and an increased heritability. Large (>500 kb) copy number variations (CNVs) previously associated with autism and schizophrenia have been reported in OCD. Recently, rare CNVs smaller than 500 kb overlapping risk loci for other neurodevelopmental conditions have also been reported in OCD, stressing the importance of examining CNVs of any size range. The aim of this study was to further investigate the role of rare and small CNVs in the aetiology of EO-OCD. Methods We performed high-resolution chromosomal microarray analysis in 121 paediatric OCD patients and in 124 random controls to identify rare CNVs (>50 kb) which might contribute to EO-OCD. Results The frequencies and the size of the observed rare CNVs in the patients did not differ from the controls. However, we observed a significantly higher frequency of rare CNVs affecting brain related genes, especially deletions, in the patients (OR = 1.98, 95% CI 1.02–3.84; OR = 3.61, 95% CI 1.14–11.41, respectively). Similarly, enrichment-analysis of CNVs gene content, performed with three independent methods, confirmed significant clustering of predefined genes involved in synaptic/brain related functional pathways in the patients but not in the controls. In two patients we detected \(de-novo\) CNVs encompassing genes previously associated with different neurodevelopmental disorders \(\textit{NRXN1, ANKS1B, UHRF1BP1}\)). Conclusions Our results further strengthen the role of small rare CNVs, particularly deletions, as susceptibility factors for paediatric OCD. KW - Medicine KW - OCD KW - CNV KW - Enrichment analysis KW - De-novo KW - Early-onset Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172791 VL - 10 IS - 68 ER - TY - JOUR A1 - Gschmack, Eva A1 - Monoranu, Camelia-Maria A1 - Marouf, Hecham A1 - Meyer, Sarah A1 - Lessel, Lena A1 - Idris, Raja A1 - Berg, Daniela A1 - Maetzler, Walter A1 - Steigerwald, Frank A1 - Volkmann, Jens A1 - Gerlach, Manfred A1 - Riederer, Peter A1 - Koutsilieri, Eleni A1 - Scheller, Carsten T1 - Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease JF - Journal of Neural Transmission N2 - Idiopathic Parkinson’s disease (PD) is characterized by a progredient degeneration of the brain, starting at deep subcortical areas such as the dorsal motor nucleus of the glossopharyngeal and vagal nerves (DM) (stage 1), followed by the coeruleus–subcoeruleus complex; (stage 2), the substantia nigra (SN) (stage 3), the anteromedial temporal mesocortex (MC) (stage 4), high-order sensory association areas and prefrontal fields (HC) (stage 5) and finally first-order sensory association areas, premotor areas, as well as primary sensory and motor field (FC) (stage 6). Autoimmunity might play a role in PD pathogenesis. Here we analyzed whether anti-brain autoantibodies differentially recognize different human brain areas and identified autoantigens that correlate with the above-described dissemination of PD pathology in the brain. Brain tissue was obtained from deceased individuals with no history of neurological or psychiatric disease and no neuropathological abnormalities. Tissue homogenates from different brain regions (DM, SN, MC, HC, FC) were subjected to SDS-PAGE and Western blot. Blots were incubated with plasma samples from 30 PD patients and 30 control subjects and stained with anti-IgG antibodies to detect anti-brain autoantibodies. Signals were quantified. Prominent autoantigens were identified by 2D-gel-coupled mass spectrometry sequencing. Anti-brain autoantibodies are frequent and occur both in healthy controls and individuals with PD. Glial fibrillary acidic protein (GFAP) was identified as a prominent autoantigen recognized in all plasma samples. GFAP immunoreactivity was highest in DM areas and lowest in FC areas with no significant differences in anti-GFAP autoantibody titers between healthy controls and individuals with PD. The anti-GFAP autoimmunoreactivity of different brain areas correlates with the dissemination of histopathological neurodegeneration in PD. We hypothesize that GFAP autoantibodies are physiological but might be involved as a cofactor in PD pathogenesis secondary to a leakage of the blood–brain barrier. KW - Parkinson KW - GFAP KW - autoantibodies KW - Braak Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325161 VL - 129 IS - 5-6 ER - TY - THES A1 - Gößler, Michael T1 - Molekulargenetische Untersuchungen serotonerger Kandidatengene bei Zwangsstörungen im Kindes- und Jugendalter T1 - Genetic studies of serotonin system candidate genes in early-onset obsessive-compulsive disorder N2 - Zwangsstörungen, im englischen als Obsessive Compulsive Disorder (OCD) bezeichnet, sind sowohl in der Erwachsenen- als auch in der Kinder- und Jugendpsychiatrie bekannte Krankheitsbilder, die mit einer Lebenszeitprävalenz von 2,5 – 3% zu den häufigsten psychiatrischen Erkrankungen im Kindes- und Jugendalter gehören. Sie stellen in der Regel eine erhebliche Belastung sowohl für die betroffenen Kinder als auch für deren Familie dar und schränken den alltäglichen Lebensablauf je nach Ausprägung erheblich ein. Familien- und Zwillingsuntersuchungen zeigen, dass bei Zwangsstörungen eine deutliche familiäre Belastung vorliegt. Gerade bei einer frühen Manifestation im Kindesalter (auf englisch als early onset bezeichnet) konnten Familienstudien zeigen, dass genetische Faktoren eine besonders ausgeprägte Rolle spielen. Diese formalgenetischen Studien legen weitere Untersuchungen auf molekulargenetischer Ebene für Zwangsstörungen im Kindes- und Jugendalter nahe. Pharmakologische Studien und erste molekulargenetische Studien verweisen zudem auf einen Zusammenhang zwischen Zwangs- und Angstsymptomen und dem Serotoninstoffwechsel. Selektive Serotonin Wiederaufnahme-Hemmer (Selective Serotonine Reuptake Inhibitors, SSRI) und tricyclische Antidepressiva sind bei der Behandlung von Zwangsstörungen besonders wirksam. Auch im Kindes- und Jugendalter sind diese Medikamente aufgrund ihrer positiven Wirkung bei Zwangsstörungen Mittel der ersten Wahl. Insgesamt wird die Pathogenese der Zwangsstörungen nach aktuellem Forschungsstand als multifaktoriell angenommen. Dabei bezieht sich bisher die überwiegende Zahl der Untersuchungen auf Zwangsstörungen erwachsener Patienten. Nach aktuellem Kenntnisstand handelt es sich bei der vorliegenden Arbeit um die ersten familienbasierten Assoziationsstudien bei Kindern und Jugendlichen mit Zwangsstörungen. Zielsetzung dieser Arbeit war die Untersuchung einer Assoziation von Varianten in ausgewählten Genen des serotonergen Systems und juvenilen Zwangsstörungen. Die Auswahl der Kandidatengene für Zwangsstörungen erfolgte auf patho-physiologischen Überlegungen: Die Tryptophanhydroxylase als geschwindigkeits-bestimmendes Enzym in der Synthese von Serotonin, der Serotonin-1B-Rezeptor als Zielorgan mit autoregulierender Funktion auf das serotonerge System, sowie der Serotonintransporter, der, therapeutisch genutzt, von SSRIs blockiert wird. Untersuchungen zu den genannten Kandidatengenen liegen bei erwachsenen Patienten mit Zwangsstörungen vor, die Ergebnisse sollten in unserer Studie repliziert werden. 64 Kinder und Jugendliche, sowie deren leibliche Eltern wurden in die Untersuchung eingeschlossen. In den vorliegenden molekulargenetischen Untersuchungen konnten für Varianten im Tryptophanhydroxylase-1-Gen und dem Serotonin-1B-Rezeptor-Gen kein Zusammenhang mit Zwangsstörungen bei Kindern und Jugendlichen gesehen werden. Die funktionelle Variante des Serotonintransporter-Gens, die zu einer höheren Aktivität des Transporters führt, wurde tendenziell häufiger bei den Patienten mit Zwangsstörungen beobachtet. Der Befund entspricht damit in der Richtung den früheren Befunden von erwachsenen Patienten. N2 - Obsessive Compulsive Disorder (OCD)is a common psychiatric disorder in adults, but also in children and adolescents. A strong genetic impact has been shown particulary in early-onset ocd. In this investigation variants of three serotonin system candidate genes (tryptophan hydroxylase 1, serotonin transporter, serotonin autoregulation-receptor 1B) were studied for an association with early-onset ocd in 64 triads. KW - Zwangsstörungen KW - Serotonin KW - Assoziationsstudie KW - Kinder und Jugendliche KW - Trios KW - ocd KW - serotonin KW - early-onset KW - association study KW - triads Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-23773 ER - TY - JOUR A1 - Hammerle, Florian A1 - Huss, Michael A1 - Ernst, Verena A1 - Bürger, Arne T1 - Thinking dimensional: prevalence of DSM-5 early adolescent full syndrome, partial and subthreshold eating disorders in a cross-sectional survey in German schools JF - BMJ Open N2 - Objectives Investigating for the first time in Germany Diagnostic and Statistical Manual Fifth Edition (DSM-5) prevalences of adolescent full syndrome, Other Specified Feeding or Eating Disorder (OSFED), partial and subthreshold anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED). Method A national school-based cross-sectional survey with nine schools in Germany was undertaken that was aimed at students from grades 7 and 8. Of the 1775 students who were contacted to participate in the study, 1654 participated (participation rate: 93.2%). The sample consisted of 873 female and 781 male adolescents (mean age=13.4 years). Prevalence rates were established using direct symptom criteria with a structured inventory (SIAB-S) and an additional self-report questionnaire (Eating Disorder Inventory 2 (EDI-2)). Results Prevalences for full syndrome were 0.3% for AN, 0.4% for BN, 0.5% for BED and 3.6% for OSFED-atypical AN, 0% for BN (low frequency/limited duration), 0% for BED (low frequency/limited duration) and 1.9% for purging disorder (PD). Prevalences of partial syndrome were 10.9% for AN (7.1% established with cognitive symptoms only, excluding weight criteria), 0.2% for BN and 2.1% for BED, and of subthreshold syndrome were 0.8% for AN, 0.3% for BN and 0.2% for BED. Cases on EDI-2 scales were much more pronounced with 12.6–21.1% of the participants with significant sex differences. Conclusions The findings were in accordance with corresponding international studies but were in contrast to other German studies showing much higher prevalence rates. The study provides, for the first time, estimates for DSM-5 prevalences of eating disorders in adolescents for Germany, and evidence in favour of using valid measures for improving prevalence estimates." KW - syndrome Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164734 VL - 6 IS - e010843 ER - TY - JOUR A1 - Hautmann, Christopher A1 - Döpfner, Manfred A1 - Katzmann, Josepha A1 - Schürmann, Stephanie A1 - Wolff Metternich-Kaizman, Tanja A1 - Jaite, Charlotte A1 - Kappel, Viola A1 - Geissler, Julia A1 - Warnke, Andreas A1 - Jacob, Christian A1 - Hennighausen, Klaus A1 - Haack-Dees, Barbara A1 - Schneider-Momm, Katja A1 - Philipsen, Alexandra A1 - Matthies, Swantje A1 - Rösler, Michael A1 - Retz, Wolfgang A1 - Gontard, Alexander von A1 - Sobanski, Esther A1 - Alm, Barbara A1 - Hohmann, Sarah A1 - Häge, Alexander A1 - Poustka, Luise A1 - Colla, Michael A1 - Gentschow, Laura A1 - Freitag, Christine M. A1 - Becker, Katja A1 - Jans, Thomas T1 - Sequential treatment of ADHD in mother and child (AIMAC study): importance of the treatment phases for intervention success in a randomized trial JF - BMC Psychiatry N2 - Background The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1) before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of the Step 2 PCT on child symptoms after the Step 1 treatment. Methods The analysis included 143 mothers and children (aged 6–12 years) both diagnosed with ADHD. The study design was a two-stage, two-arm parallel group trial (Step 1 treatment group [TG]: intensive treatment of the mother including psychotherapy and pharmacotherapy; Step 1 control group [CG]: supportive counseling only for mother; Step 2 TG and CG: PCT). Single- and multi-group analyses with piecewise linear latent growth curve models were applied to test for the effects of group and phase. Child symptoms (e.g., ADHD symptoms, disruptive behavior) were rated by three informants (blinded clinician, mother, teacher). Results Children in the TG showed a stronger improvement of their disruptive behavior as rated by mothers than those in the CG during Step 1 (Step 1: TG vs. CG). In the CG, according to reports of the blinded clinician and the mother, the reduction of children’s disruptive behavior was stronger during Step 2 than during Step 1 (CG: Step 1 vs. Step 2). In the TG, improvement of child outcome did not differ across treatment steps (TG: Step 1 vs. Step 2). Conclusions Intensive treatment of the mother including pharmacotherapy and psychotherapy may have small positive effects on the child’s disruptive behavior. PCT may be a valid treatment option for children with ADHD regarding disruptive behavior, even if mothers are not intensively treated beforehand. Trial registration ISRCTN registry ISRCTN73911400. Registered 29 March 2007. KW - mothers KW - children KW - adult treatment KW - parent training KW - efficacy Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227930 VL - 18 ER - TY - JOUR A1 - Havik, Bjarte A1 - Degenhardt, Franziska A. A1 - Johansson, Stefan A1 - Fernandes, Carla P. D. A1 - Hinney, Anke A1 - Scherag, André A1 - Lybaek, Helle A1 - Djurovic, Srdjan A1 - Christoforou, Andrea A1 - Ersland, Kari M. A1 - Giddaluru, Sudheer A1 - O'Donovan, Michael C. A1 - Owen, Michael J. A1 - Craddock, Nick A1 - Mühleisen, Thomas W. A1 - Mattheisen, Manuel A1 - Schimmelmann, Benno G. A1 - Renner, Tobias A1 - Warnke, Andreas A1 - Herpertz-Dahlmann, Beate A1 - Sinzig, Judith A1 - Albayrak, Özgür A1 - Rietschel, Marcella A1 - Nöthen, Markus M. A1 - Bramham, Clive R. A1 - Werge, Thomas A1 - Hebebrand, Johannes A1 - Haavik, Jan A1 - Andreassen, Ole A. A1 - Cichon, Sven A1 - Steen, Vidar M. A1 - Le Hellard, Stephanie T1 - DCLK1 Variants Are Associated across Schizophrenia and Attention Deficit/Hyperactivity Disorder JF - PLoS One N2 - Doublecortin and calmodulin like kinase 1 (DCLK1) is implicated in synaptic plasticity and neurodevelopment. Genetic variants in DCLK1 are associated with cognitive traits, specifically verbal memory and general cognition. We investigated the role of DCLK1 variants in three psychiatric disorders that have neuro-cognitive dysfunctions: schizophrenia (SCZ), bipolar affective disorder (BP) and attention deficit/hyperactivity disorder (ADHD). We mined six genome wide association studies (GWASs) that were available publically or through collaboration; three for BP, two for SCZ and one for ADHD. We also genotyped the DCLK1 region in additional samples of cases with SCZ, BP or ADHD and controls that had not been whole-genome typed. In total, 9895 subjects were analysed, including 5308 normal controls and 4,587 patients (1,125 with SCZ, 2,496 with BP and 966 with ADHD). Several DCLK1 variants were associated with disease phenotypes in the different samples. The main effect was observed for rs7989807 in intron 3, which was strongly associated with SCZ alone and even more so when cases with SCZ and ADHD were combined (P-value = 4x10\(^{-5}\) and 4x10\(^{-6}\), respectively). Associations were also observed with additional markers in intron 3 (combination of SCZ, ADHD and BP), intron 19 (SCZ+BP) and the 3'UTR (SCZ+BP). Our results suggest that genetic variants in DCLK1 are associated with SCZ and, to a lesser extent, with ADHD and BP. Interestingly the association is strongest when SCZ and ADHD are considered together, suggesting common genetic susceptibility. Given that DCLK1 variants were previously found to be associated with cognitive traits, these results are consistent with the role of DCLK1 in neurodevelopment and synaptic plasticity. KW - psychosis KW - deficit hyperactivity disorder KW - genome-wide association KW - bipolar disorder KW - VAL66MET polymorphism KW - doublecortine-like KW - genes KW - kinase KW - BDNF KW - endophenotype Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-135285 VL - 7 IS - 4 ER - TY - JOUR A1 - Hebestreit, Helge A1 - Zeidler, Cornelia A1 - Schippers, Christopher A1 - de Zwaan, Martina A1 - Deckert, Jürgen A1 - Heuschmann, Peter A1 - Krauth, Christian A1 - Bullinger, Monika A1 - Berger, Alexandra A1 - Berneburg, Mark A1 - Brandstetter, Lilly A1 - Deibele, Anna A1 - Dieris-Hirche, Jan A1 - Graessner, Holm A1 - Gündel, Harald A1 - Herpertz, Stephan A1 - Heuft, Gereon A1 - Lapstich, Anne-Marie A1 - Lücke, Thomas A1 - Maisch, Tim A1 - Mundlos, Christine A1 - Petermann-Meyer, Andrea A1 - Müller, Susanne A1 - Ott, Stephan A1 - Pfister, Lisa A1 - Quitmann, Julia A1 - Romanos, Marcel A1 - Rutsch, Frank A1 - Schaubert, Kristina A1 - Schubert, Katharina A1 - Schulz, Jörg B. A1 - Schweiger, Susann A1 - Tüscher, Oliver A1 - Ungethüm, Kathrin A1 - Wagner, Thomas O. F. A1 - Haas, Kirsten T1 - Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study JF - Orphanet Journal of Rare Diseases N2 - Background In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. Study design This multi-center, prospective controlled study has a two-phase cohort design. Methods Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). Outcomes Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach. Conclusions This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease. KW - rare diseases KW - multi‑center cohort study KW - dual guidance Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-300440 VL - 17 IS - 1 ER - TY - THES A1 - Hench, Franz T1 - Familienuntersuchung bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS): Komorbiditäten und familiäre Belastung T1 - Family-Investigation of Children and Adolescent with Attention-Deficit/Hyperactivity Disorder (ADHD): Comorbidity and Family History N2 - Die Aufmerksamkeitsdefizit- /Hyperaktivitätsstörung (ADHS) gilt heute als eine der häufigsten Erkrankungen, die in der Kinder- und Jugendpsychiatrie bzw. in der Kinder- und Jugendmedizin behandelt werden. Bei diesem Störungsbild spielen genetische Faktoren eine wichtige Rolle. Erblichkeitsschätzungen liegen bei bis zu 80% und damit höher als bei den meisten kinder- und jugendpsychiatrischen Erkrankungen. Das Ziel der vorliegenden Arbeit war die Erhebung epidemiologischer und soziodemographischer Daten, komorbider Störungen in Abhängigkeit von vorliegenden Subtypen bei ADHS nach DSM-IV sowie die Untersuchung der Prävalenz für eine ADHS bei Eltern in Familien mit mindestens zwei an ADHS erkrankten Kindern. Methode: Es wurde N = 64 Patienten aus 25 Familien mit mindestens zwei an ADHS erkrankten Kindern untersucht. Die Stichprobe wurde im Rahmen einer multizentrischen Familienuntersuchung zu genetischen Faktoren ADHS (Nationales Genomforschungsnetz) erhoben. Die Diagnose der ADHS und Erhebung komorbider Störungen der betroffenen Kinder erfolgte nach DSM-IV-Kriterien unter Zuhilfenahme des K-SADS-PL. Bei den Eltern wurde die Wender-Utah-Rating-Scale (WURS) verwendet. Ergebnis: Bei Patienten mit kombiniertem Subtyp einer ADHS nach DSM-IV wurden signifikant häufiger externalisierende Störungen diagnostiziert. Betroffene Kinder mit überwiegend unaufmerksamen Subtyp litten häufiger an internalisierenden Störungen und bei ihnen wurde die Diagnose signifikant später gestellt als bei Kindern mit einem anderen Subtyp nach DSM-IV. Im Vergleich mit Studien in denen Familien mit nur einem betroffenen Kind untersucht wurden zeigten sich im wesentlichen keine signifikanten Unterschiede in der Verteilung der häufigsten komorbiden Störungen bei den betroffenen Kindern. Insgesamt fanden wir, dass 48% der Mütter und 43% der Väter im Kindesalter von einer ADHS betroffen waren. Auf alle Familien verteilt, ergab sich eine mindestens einfache Belastung der Eltern von ca. 78%. N2 - Attention-deficit/hyperactivity disorder (ADHD) is one of the most common disorders treated in child and adolescent psychiatry and in paediatrics. Hereditary factors seem to be most important. Heritability is estimated up to 80%. Thus, it is one of the highest rates in whole disorders of child and adolescent psychiatry. It was the aim of this investigation to examine epidemiological and demographic data, comorbidity depending on the very subtype of ADHD and prevalence of ADHD in parents of families with affected siblings. Method: 64 affected siblings in 25 families were examined. All families took part in a genome scan of ADHD (Nationales Genomforschungsnetz). ADHD diagnoses and comorbid disorders were evaluated with K-SADS-PL based on DSM-IV criteria. Parents completed Wender-Utah-Rating-Scale (WURS). Results: The rate of externalizing disorders is significantly higher in affected children with a combined type of ADHD. Inattentive children suffer more often from internalizing disorders and diagnoses were found significantly later. The rates of comorbidities are comparable with results of investigations in families with just one affected child. 48% of the mothers and 43% of the fathers met the criteria for ADHD in their childhood. Among the 25 parents we found at least one parent with ADHD in 78% of all families. KW - ADHS KW - Familienuntersuchung KW - Komorbiditäten KW - ADHS KW - Familienuntersuchung KW - Komorbiditäten KW - ADHD KW - Family-Investigation KW - Comorbidity Y1 - 2007 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-35494 ER - TY - THES A1 - Herhaus, Gabriele T1 - Besteht ein Zusammenhang zwischen Symptomen der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung in der Kindheit sowie ihrer Pharmakotherapie und dem späteren Auftreten eines Parkinson-Syndroms? T1 - Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood N2 - Die ADHS und die Parkinson-Krankheit gehen beide mit Veränderungen des dopaminergen Systems einher. Methylphenidat (MPH) ist ein zentralwirkendes Psychostimulans, das den Dopamin-Wiederaufnahme-Transporter reversibel hemmt. Obwohl MPH seit über 50 Jahren in der symptomatischen Therapie der ADHS angewandt wird, ist die Datenlage zu den Langzeiteffekten und Risiken dieses Medikaments relativ dünn. Basierend auf den Ergebnissen von Versuchen an Ratten wurde die Theorie aufgestellt, dass MPH die Ausreifung des zentralen dopaminergen Systems beeinflusst und dadurch ein Risikofaktor für die Entwicklung eines Parkinson-Syndroms sein könnte. Ziel dieser Pilotstudie war zum einen zu untersuchen, ob bei Patienten mit Parkinson ADHS-ähnliche Symptome in der Kindheit auftraten und zum anderen zu ermitteln, ob Parkinson-Patienten in ihrer Kindheit Psychostimulanzien eingenommen haben. Als Instrumentarium dienten die deutsche Kurzform der Wenda Utah Rating Scale (WURS-k) sowie der ‘Fragebogen zu Kindheit und Entwicklung U40‘. Insgesamt füllten 88 Parkinson-Patienten die Fragebögen vollständig aus. Die Daten dieser Patienten sowie einer ebenso großen, randomisierten Kontrollgruppe wurden in die Auswertung einbezogen. Im Fragebogen WURS-k fanden sich in der Gruppe der Parkinson-Patienten signifikant höhere Summenscores im Vergleich zur Kontrollgruppe. Zusätzlich zeigten sich bei den Parkinson-Patienten höhere Scores bezüglich der Faktoren „Aufmerksamkeitsdefizit/Hyperaktivität“ sowie „ängstlich-depressive Symptomatik“, nicht aber bei den Faktoren „Impulsivität“, „Protestverhalten“ und „Störung der sozialen Adaptation“. Auch die Auswertung des Fragebogens U40 ergab signifikant höhere Punktwerte bezüglich der Items „Aufmerksamkeitsdefizit“ und „Hyperaktivität“ bei den Parkinson-Patienten. Dennoch kann aus diesen Ergebnissen nicht geschlossen werden, dass die in unserer Studie untersuchten Parkinson-Patienten in ihrer Kindheit an einer ADHS litten, da die durchschnittlichen Summenscores der WURS-k deutlich unter dem festgelegten Cut-Off-Wert von größer oder gleich 30 lagen. Es ist aber möglich, dass einzelne ADHS-ähnliche Symptome den motorischen Symptomen einer Parkinson-Erkrankung vorausgehen können. Letztlich fanden wir keinen Anhalt dafür, dass die Parkinson-Patienten in ihrer Kindheit Psychostimulanzien wie MPH eingenommen hatten. N2 - Attention deficit hyperactivity disorder (ADHD) and Parkinson’s disease (PD) are attended by alterations in the dopaminergic system. Methylphendiate (MPH) is a central acting psychostimulant which reversibly blocks the dopamine re-uptake transporter. At present MPH ist one of the most frequently prescribed drugs for the symptomatic treatment of ADHD. Although MPH has been in use for over 50 years, there is only little information available concerning the long-term benefits and risks of medication. Based on experiments in rats it has been suggested that MPH treatment may affect the maturation of the central dopaminergic system and may be a risk factor for the development of PD. The aim of the present case-control study was to gain information about (1) ADHD-like symptoms that may precede PD symptoms and (2) the exposure to psychostimulants in childhood. We used a German short version of the Wender Utah Rating Scale (WURS-k) which is a reliable measure for the retrospective diagnosis of childhood ADHD and another questionnaire the „Quesionnaire to Childhood and Development U40“. A total of 88 PD patients completed the two rating scales. The data of these patients and of 88 randomly selected individuals of the controls were included for analysis. In the WURS-k, the PD group showed higher total scores compared to control subjects. In addition, we found increased scores in PD patients regarding the items „attention deficit“, „hyperactivity“ and „anxious and depressive symptoms“, but not regarding „impulsivity“, „oppositional behaviour“ and „deficits in social adaptation“. The results of the U40 also showed increased scores in PD patients regarding „attention deficit“ and „hyperactivity“. However, one cannot conclude that the PD patients enrolled in this study had suffered form childhood ADHD, since the average total WURS-k score was far below the cut-off score of 30 or higher. But it is possible that ADHD-like symtoms precede the characteristical PD symptoms. Finally, we found no evidence that PD patients had been exposed to psychostimulants such as MPH. KW - ADHS KW - Parkinson-Krankheit KW - Methylphenidat Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126191 ER - TY - JOUR A1 - Herzog, Katharina A1 - Andreatta, Marta A1 - Schneider, Kristina A1 - Schiele, Miriam A. A1 - Domschke, Katharina A1 - Romanos, Marcel A1 - Deckert, Jürgen A1 - Pauli, Paul T1 - Reducing Generalization of Conditioned Fear: Beneficial Impact of Fear Relevance and Feedback in Discrimination Training JF - Frontiers in Psychology N2 - Anxiety patients over-generalize fear, possibly because of an incapacity to discriminate threat and safety signals. Discrimination trainings are promising approaches for reducing such fear over-generalization. Here we investigated the efficacy of a fear-relevant vs. a fear-irrelevant discrimination training on fear generalization and whether the effects are increased with feedback during training. Eighty participants underwent two fear acquisition blocks, during which one face (conditioned stimulus, CS+), but not another face (CS−), was associated with a female scream (unconditioned stimulus, US). During two generalization blocks, both CSs plus four morphs (generalization stimuli, GS1–GS4) were presented. Between these generalization blocks, half of the participants underwent a fear-relevant discrimination training (discrimination between CS+ and the other faces) with or without feedback and the other half a fear-irrelevant discrimination training (discrimination between the width of lines) with or without feedback. US expectancy, arousal, valence ratings, and skin conductance responses (SCR) indicated successful fear acquisition. Importantly, fear-relevant vs. fear-irrelevant discrimination trainings and feedback vs. no feedback reduced generalization as reflected in US expectancy ratings independently from one another. No effects of training condition were found for arousal and valence ratings or SCR. In summary, this is a first indication that fear-relevant discrimination training and feedback can improve the discrimination between threat and safety signals in healthy individuals, at least for learning-related evaluations, but not evaluations of valence or (physiological) arousal. KW - fear generalization KW - feedback KW - discrimination training KW - fear-relevant training KW - classical conditioning Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-239970 SN - 1664-1078 VL - 12 ER - TY - THES A1 - Hohage, Amelie T1 - Überprüfung der Eignung des Kiddie-SADS-Interviews zur dimensionalen Erfassung der externalen Symptomatik bei Kindern und Jugendlichen mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung - Eine empirische Untersuchung T1 - Examination of the Kiddie-SADS for a dimensional assessmentof externalizing symptoms in ADHD children and adolescents N2 - In der vorliegenden Arbeit sollte ein Interview auf die Gütekriterien Objektivität, Validität und Reliabilität überprüft werden. Es sollte untersucht werden, ob das Interview geeignet ist, aktuell vorhandene Symptome der ADHS und der ODD dimensional zu erfassen. Dabei wurden 61 Patienten der Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und Psychotherapie der Universität Würzburg mit ihren Müttern befragt. Die Objektivität wurde überprüft, indem das Interview auf Video aufgezeichnet und nochmals von einem zweiten Beurteiler ausgewertet wurde. Die Summenwerte der beiden Interviewer wurden miteinander korreliert. Die Korrelation war signifikant und ergab einen Wert von rk= ,98. Die Objektivität im Sinne der Beurteilerübereinstimmung kann somit als hoch angesehen werden. Es konnte gezeigt werden, dass die zusammenfassende Beurteilung des Interviewers höher mit der Einschätzung aufgrund der Angaben der Mütter korreliert als mit der Einschätzung aufgrund der Angaben der Kinder. Die Korrelation zwischen der zusammenfassenden Beurteilung und der Einschätzung aufgrund der Angaben der Müttern ergab einen Wert von r= ,98, die Korrelation zwischen der zusammenfassenden Beurteilung und der Einschätzung aufgrund der Angaben der Kindern einen Wert von r= ,57. Die zusammenfassende Beurteilung des Interviewers gründet demnach im Wesentlichen auf den Angaben der Mütter. Die Konstruktvalidität wurde ermittelt, indem das Interview mit anderen diagnostischen Verfahren verglichen wurde. Die Korrelation des Interviews mit ADHS-nahen Konstrukten war signifikant und ergab Werte zwischen rtc= ,48 und rtc= ,70. Die diskriminante Validität wurde durch Korrelation mit ADHS-fernen Konstrukten ermittelt. Der Korrelationskoeffizient betrug rtc= ,27. Die Validität liegt somit im mittleren bis oberen Bereich. Ebenfalls wurde belegt, dass Kinder mit zusätzlicher Störung des Sozialverhaltens einen höheren Gesamtscore im Interview erreichen. Das Interview diskriminiert demnach erwartungsgemäß zwischen ADHS-Patienten mit zusätzlicher Störung des Sozialverhaltens und ADHS-Patienten ohne zusätzliche Störung. Die Überprüfung der Gütekriterien erzielte gute Ergebnisse für Objektivität und Validität. Demnach werden Symptome der ADHS und der oppositionellen Störung des Sozialverhaltens mit dem untersuchten Verfahren in hinreichender Güte erfasst. N2 - The psychometric properties of an interview based on the Kiddie-SADS used for a dimensional assessment of externalizing symptoms in children and adolescents was examined. Therefore, 61 patients and their mothers were interviewed. The Interviews were videotaped and rated again by a second rater. The Interrater-correlation of the ADHD–ODD scores was r = 0.98. Convergent and discriminant validity were showed middle to high correlations with mother-ratings of the children’s externalizing symptoms and a low correlation with ratings of internalizing symptoms. Ratings of the interviewer were based on mother- ratings (r = .98). In summary the examined interview allows a reliable and valid dimensional assessment of externalizing symptoms in children and adolescents with ADHD. KW - Aufmerksamkeits-Defizit-Syndrom KW - Interview KW - K-SADS KW - atention deficit order Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-73984 ER - TY - THES A1 - Holweck, Julia T1 - Putative Biomarker neuropsychiatrischer Entwicklungskomorbiditäten beim Deletionssyndrom 22q11.2 T1 - Potential biomarkers of neuropsychiatric comorbidities in 22q11.2 Deletion Syndrome N2 - Vom Deletionssyndrom 22q11.2 Betroffene sind einem überdurchschnittlich hohen Risiko ausgesetzt im Entwicklungsverlauf psychisch zu erkranken. Häufige Störungsbilder sind unter anderem ADHS, Angsterkrankungen, affektive Störungen, Erkrankungen aus dem schizophrenen Formenkreis und Morbus Parkinson. Ziel der Studie war es, phänotypische Auffälligkeiten beim DS22q11 zu identifizieren, die dabei helfen könnten, Hochrisikogruppen innerhalb des Syndroms frühzeitig identifizieren zu können und in Form von Biomarkern messbar sind. Hierzu wurden die bereits in Forschung und teilweise auch in der Klinik etablierten Verfahren der transkraniellen Sonographie und der standardisierten Riechtestung eingesetzt. N2 - Individuals affected with 22q11.2 Deletion Syndrome (22q11.2DS) are at an above average risk to develop neuropsychiatric disorders (such as attention-deficit/hyperactivity disorder, anxiety disorders, affective disorders, schizophrenia and Parkinson's disease). The aim of this study is to identify phenotypical characteristics in 22q11.2DS to help point out high-risk groups within the syndrome and then be measured as biomarkers. To achieve this, we performed transcranial sonography and olfactory testing which are known to be established clinical and research methods. KW - Mikrodeletionssyndrom 22q11 KW - Substantia nigra KW - Ultraschalldiagnostik KW - Geruchssinn KW - Biomarker KW - Transkranieller Ultraschall Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-292915 ER - TY - JOUR A1 - Hommers, L. G. A1 - Richter, J. A1 - Yang, Y. A1 - Raab, A. A1 - Baumann, C. A1 - Lang, K. A1 - Schiele, M. A. A1 - Weber, H. A1 - Wittmann, A. A1 - Wolf, C. A1 - Alpers, G. W. A1 - Arolt, V. A1 - Domschke, K. A1 - Fehm, L. A1 - Fydrich, T. A1 - Gerlach, A. A1 - Gloster, A. T. A1 - Hamm, A. O. A1 - Helbig-Lang, S. A1 - Kircher, T. A1 - Lang, T. A1 - Pané-Farré, C. A. A1 - Pauli, P. A1 - Pfleiderer, B. A1 - Reif, A. A1 - Romanos, M. A1 - Straube, B. A1 - Ströhle, A. A1 - Wittchen, H.-U. A1 - Frantz, S. A1 - Ertl, G. A1 - Lohse, M. J. A1 - Lueken, U. A1 - Deckert, J. T1 - A functional genetic variation of SLC6A2 repressor hsa-miR-579-3p upregulates sympathetic noradrenergic processes of fear and anxiety JF - Translational Psychiatry N2 - Increased sympathetic noradrenergic signaling is crucially involved in fear and anxiety as defensive states. MicroRNAs regulate dynamic gene expression during synaptic plasticity and genetic variation of microRNAs modulating noradrenaline transporter gene (SLC6A2) expression may thus lead to altered central and peripheral processing of fear and anxiety. In silico prediction of microRNA regulation of SLC6A2 was confirmed by luciferase reporter assays and identified hsa-miR-579-3p as a regulating microRNA. The minor (T)-allele of rs2910931 (MAFcases = 0.431, MAFcontrols = 0.368) upstream of MIR579 was associated with panic disorder in patients (pallelic = 0.004, ncases = 506, ncontrols = 506) and with higher trait anxiety in healthy individuals (pASI = 0.029, pACQ = 0.047, n = 3112). Compared to the major (A)-allele, increased promoter activity was observed in luciferase reporter assays in vitro suggesting more effective MIR579 expression and SLC6A2 repression in vivo (p = 0.041). Healthy individuals carrying at least one (T)-allele showed a brain activation pattern suggesting increased defensive responding and sympathetic noradrenergic activation in midbrain and limbic areas during the extinction of conditioned fear. Panic disorder patients carrying two (T)-alleles showed elevated heart rates in an anxiety-provoking behavioral avoidance test (F(2, 270) = 5.47, p = 0.005). Fine-tuning of noradrenaline homeostasis by a MIR579 genetic variation modulated central and peripheral sympathetic noradrenergic activation during fear processing and anxiety. This study opens new perspectives on the role of microRNAs in the etiopathogenesis of anxiety disorders, particularly their cardiovascular symptoms and comorbidities. KW - clinical genetics KW - psychiatric disorders Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-322497 VL - 8 ER - TY - JOUR A1 - Härtel, Christoph A1 - Spiegler, Juliane A1 - Fortmann, Ingmar A1 - Astiz, Mariana A1 - Oster, Henrik A1 - Siller, Bastian A1 - Viemann, Dorothee A1 - Keil, Thomas A1 - Banaschewski, Tobias A1 - Romanos, Marcel A1 - Herting, Egbert A1 - Göpel, Wolfgang T1 - Breastfeeding for 3 months or longer but not probiotics is associated with reduced risk for inattention/hyperactivity and conduct problems in very-low-birth-weight children at early primary school age JF - Nutrients N2 - (1) Background: We aimed to evaluate the effect of proposed “microbiome-stabilising interventions”, i.e., breastfeeding for ≥3 months and prophylactic use of Lactobacillus acidophilus/ Bifidobacterium infantis probiotics on neurocognitive and behavioral outcomes of very-low-birthweight (VLBW) children aged 5–6 years. (2) Methods: We performed a 5-year-follow-up assessment including a strength and difficulties questionnaire (SDQ) and an intelligence quotient (IQ) assessment using the Wechsler Preschool and Primary Scale of Intelligence (WPPSI)-III test in preterm children previously enrolled in the German Neonatal Network (GNN). The analysis was restricted to children exposed to antenatal corticosteroids and postnatal antibiotics. (3) Results: 2467 primary school-aged children fulfilled the inclusion criteria. In multivariable linear regression models breastfeeding ≥3 months was associated with lower conduct disorders (B (95% confidence intervals (CI)): −0.25 (−0.47 to −0.03)) and inattention/hyperactivity (−0.46 (−0.81 to −0.10)) as measured by SDQ. Probiotic treatment during the neonatal period had no effect on SDQ scores or intelligence. (4) Conclusions: Prolonged breastfeeding of highly vulnerable infants may promote their mental health later in childhood, particularly by reducing risk for inattention/hyperactivity and conduct disorders. Future studies need to disentangle the underlying mechanisms during a critical time frame of development. KW - breastfeeding KW - probiotic prophylaxis KW - preterm children KW - strength and difficulties KW - inattention/hyperactivity KW - intelligence Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-216319 SN - 2072-6643 VL - 12 IS - 11 ER - TY - THES A1 - Häußler, Marie T1 - Untersuchung der kardialen autonomen Regulation anhand der Herzfrequenzvariabilität bei depressiven Kindern und Jugendlichen im Vergleich zu gesunden Kontrollen - eine Pilotstudie mit Querschnitts- und Längsschnittanalysen T1 - Examination of cardiac autonomic regulation based on the heart rate variability in of depressed Children and Adolescents in comparison with healthy controls – a pilot study including cross-sectional and longitudinal analyses N2 - Bei Erwachsenen ist ein Zusammenhang zwischen Depressionen und Herzerkrankungen bekannt. Als möglicher Mechanismus hierfür gilt eine Veränderung der kardialen autonomen Funktion, messbar über eine verminderte Herzfrequenzvariabilität (HRV) und eine höhere Herzfrequenz. Es finden sich in der Literatur erste Hinweise, dass auch bei Kindern und Jugendlichen mit Depressionen Veränderungen der kardialen autonomen Regulation zu beobachten sind. In der vorliegenden Studie an der Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie Würzburg wurde erstmals die kardiale autonome Funktion bei depressiven Kindern und Jugendlichen mit Hilfe von Langzeit-EKGs untersucht. Geprüft wurde hierbei, ob depressive Störungen im Kindes- und Jugendalter mit einer gestörten kardialen autonomen Regulation in Form einer verminderten HRV und einer erhöhten Herzfrequenz vergesellschaftet sind. Zudem wurde der Einfluss einer antidepressiven Therapie untersucht. Die Ergebnisse der Studie zeigen, dass depressive Kinder und Jugendliche im Vergleich zu gesunden eine signifikant höhere mittlere Herzfrequenz im Langzeit-EKG aufweisen. Zudem hatten sie leicht verminderte HRV-Parameter, wobei dieser Unterschied nicht statistisch signifikant war. Eine Veränderung der HRV oder der Herzfrequenz im Therapieverlauf konnte nicht belegt werden. Weitere größere Studien sind nötig, um die Zusammenhänge zwischen Depressionen und Veränderungen der kardialen autonomen Funktion im Kindes- und Jugendalter zu erforschen. N2 - In adults, a correlation between depression and heart diseases is known. One potential pathophysiological mechanism is the change of the cardiac autonomic function, which can be measured by decreased heart rate variability (HRV) and higher heart rate. There are few first studies indicating that changes of the cardiac autonomic regulation can be observed in depressed children and adolescents, too. In this study at the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (University of Wuerzburg), the cardiac autonomic function in depressed children and adolescents was assessed with long-term ECGs. We examined, if depression in childhood and adolescence is associated with an altered cardiac autonomic regulation with reduced HRV and higher heart rate. Furthermore, we examined the influence of antidepressant treatment. Our Data shows, that depressed children and adolescents have a significantly higher mean heart rate than healthy controls. They had slightly diminished HRV parameters as well. This difference, however, was not statistically significant. There were no changes of HRV or heart rate during the therapy of depression. Further larger studies are needed to clarify the relation between depression and changes of the cardiac autonomic function in childhood and adolescence. KW - Herzfrequenzvariabilität KW - Depression KW - Kinder- und Jugendpsychiatrie Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-168750 ER - TY - THES A1 - Hüttl, Fabian T1 - Motorische Fertigkeiten von Kindern und Jugendlichen mit psychischen Störungen – eine retrospektive Analyse T1 - Motor skills of children and adolescents with psychiatric disorders - a retrospective analysis N2 - Durch die vorliegende Arbeit konnte störungsübergreifend ein Zusammenhang zwischen dem Tag der Motorik-Testung und dem IQ einerseits und den Testbefunden zur Motorik andererseits gezeigt werden. Es gelang nicht, den vermuteten negativen Einfluss von psychosozialen Faktoren auf motorische Fähigkeiten zu demonstrieren. Bezüglich der ADHS-Medikation konnte aufgrund des Studiendesigns als Querschnittstudie keine klare Aussage getroffen werden, ob ein positiver Einfluss auf motorische Fähigkeiten vorliegt. Bei den Patient-/innen mit Hyperkinetischer Störung des Sozialverhaltens (F90.1) fanden sich zwar bei bestehender ADHS-Medikation signifikant bessere Testbefunde der Balance, es konnte jedoch nicht geklärt werden, warum der positive Effekt der ADHS-Medikation nur auf diese Störungsgruppe und den Balance-Untertest der M-ABC II begrenzt war. Im Gruppenvergleich konnten signifikant bessere motorische Fähigkeiten der Patient-/innen mit internalisierender Störung als jener mit externalisierender Störung festgestellt werden. Damit kongruent kam die Diagnose einer UEMF (F82) in der Gruppe der externalisierenden Störungen häufiger vor. Da ein Großteil der Patient-/innen der externalisierenden Störungsgruppe an Defiziten der Aufmerksamkeit, Impulskontrolle und der Motivation litt, ist davon auszugehen, dass diese Symptome zu schwerwiegenden Beeinträchtigungen der motorischen Fähigkeiten und damit auch zu weiteren Problemen im Alltag oder bei der Schullaufbahn führen. Innerhalb der Gruppe der externalisierenden Störungen konnte hinsichtlich der motorischen Fähigkeiten kein Unterschied zwischen Patient-/innen mit Hyperkinetischen Störungen (F90.-) und solchen mit Störung des Sozialverhaltens (F91) gefunden werden. Ein solcher Unterschied hätte einen Hinweis geben können, ob eher Defizite der Aufmerksamkeit und Impulskontrolle oder ein Motivationsdefizit mit motorischen Einschränkungen verbunden sind. Hierbei ist anzumerken, dass die Gruppengrößen für einen validen Vergleich dieser Störungsgruppen nicht ausreichend waren. Der Vergleich motorischer Fähigkeiten sowie der Häufigkeit einer UEMF (F82) zwischen Patient-/innen mit umschriebener Entwicklungsstörung des Sprechens und der Sprache (F80) einerseits und Patient-/innen mit umschriebener Entwicklungsstörung der schulischen Fertigkeiten (F81) andererseits bestätigte die Vermutung, dass bei Patient-/innen der Störungsgruppe F80 schlechtere motorische Fähigkeiten und signifikant mehr motorische Defizite vorlagen. Ein Teil dieses Unterschieds lässt sich jedoch durch den signifikant niedrigeren IQ der Störungsgruppe F80 erklären. Es muss darüber hinaus berücksichtigt werden, dass bei den umschriebenen Entwicklungsstörungen F80 und F81 eine häufige Komorbidität mit externalisierenden Störungen bestand, sodass motorische Defizite auch durch ein ursächliches Defizit der Aufmerksamkeit und Impulskontrolle erklärt werden könnten. N2 - The findings of this dissertation showed a connection between the IQ and the timing of motor function testing with test results in a group of children and adolescents afflicted with a psychiatric disorder. Furthermore differences in motor test results between several diagnostic groups were identified allowing for an insight into the pathogenesis of motor function deficiencies. KW - Motorische Fähigkeit KW - Psychische Störung KW - Motorische Fertigkeiten Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-321905 ER - TY - THES A1 - Hütz, Barbara T1 - Substantia Nigra-Echogenität als Biomarker für Erkrankungen aus dem psychotischen Formenkreis und Korrelat psychopharmakologischer Nebenwirkungen bei Jugendlichen und jungen Erwachsenen T1 - Substantia Nigra echogenicity as biomarker for schizophrenic spectrum disorders and neuroleptic-induced extrapyramidal side-effects in adolescents and young adults N2 - Hintergrund: Bei erwachsenen Patient*innen mit Erkrankungen aus dem Schizophrenie-Spektrum konnte im transkraniellen Ultraschall im Vergleich zu gesunden Proband*innen eine signifikant erhöhte Echogenität der Substantia Nigra (SN) nachgewiesen werden. Zudem bestand ein Zusammenhang zwischen der SN-Fläche und stärker ausgeprägten extrapyramidalmotorischen Bewegungsstörungen unter Antipsychotikatherapie. In der vorliegenden Arbeit wurde überprüft, inwiefern die Echogenität der SN auch bei Jugendlichen und jungen Erwachsenen als Biomarker für Erkrankungen aus dem psychotischen Formenkreis und als Korrelat psychopharmakologischer Nebenwirkungen herangezogen werden kann. Des Weiteren wurde der Einfluss von Alter, Krankheitsdauer sowie Antipsychotika-Lebenszeitdosis auf die SN-Echogenität untersucht sowie Zusammenhänge mit peripheren Eisenparametern. Methoden: Hierfür wurden insgesamt 16 stationär behandelte Patient*innen zwischen 14 – 22 Jahren mit Erkrankungen aus dem schizophrenen Formenkreis sowie nach Alter und Geschlecht gematchte gesunde Kontrollen mittels TCS untersucht. Aus peripher entnommenem Blut wurden Parameter des Eisenhaushalts bestimmt. Ergebnisse: Es konnten entgegen der Hypothese keine signifikanten Unterschiede in Bezug auf die Echogenität der SN im Vergleich zur gesunden Kontrollgruppe festgestellt werden. Bezüglich der Schwere der beobachteten EPMS ergab sich entgegen der Hypothese und im Kontrast zu Befunden bei Erwachsenen kein Zusammenhang mit der SN-Echogenität. Das Alter der Proband*innen, die Krankheitsdauer sowie die Dosis der eingenommenen Antipsychotika zeigten keine Zusammenhänge mit der SN-Echogenität. Interessanterweise zeigte sich eine signifikant negative Korrelation zwischen der echogenen Fläche der SN und Eisen sowie Transferrin. Schlussfolgerung: Im Jugend- und jungen Erwachsenenalter eignet sich die SN-Echogenität vermutlich nicht als Biomarker für Erkrankungen aus dem Schizophrenie-Spektrum oder für die Prädiktion von Nebenwirkungen antipsychotischer Medikation. Möglicherweise manifestiert sich eine erhöhte Echogenität der SN, welche als Zeichen für eine Schädigung der dopaminergen Neurone gesehen wird, bei schizophrenen Psychosen erst im Verlauf der Krankheit. Da wir die Studienteilnehmer*innen nur zu einem einzigen Zeitpunkt im Laufe ihrer Krankheitsgeschichte untersuchten, kann keine Aussage über den weiteren Verlauf der SN-Echogenität getroffen werden. Hierfür wären longitudinale Untersuchungen zielführend, da nur so mögliche entwicklungsbedingte Veränderungen festgestellt werden können. N2 - Background: Adult patients with schizophrenic spectrum disorders showed a significantly larger mean echogenic area of the subtantia nigra (SN) in transcranial sonography compared to healthy controls. Also, patients showing larger echogenic SN developed more severe neuroleptic-induced extrapyramidal side-effects. In this study, we examined if SN echogenicity can function as a biomarker for schizophrenic spectrum disorders and as a predictor of neuroleptic-induced extrapyramidal side-effects in adolescents and young adults. Furthermore, we investigated the correlation of age, disease duration, lifetime neuroleptic dose and iron parameters with SN echogenicity. Methods: 16 hospitalized patients who had been diagnosed with schizophrenic spectrum disorders and 16 healthy controls between the ages of 14 – 22 years were examined via transcranial sonography. We also assessed the concentration of iron parameters in peripheral blood samples. Results: In contradiction to our hypothesis, no significant differences regarding SN echogenicity could be found when comparing the two groups. There also was no correlation of severity of extrapyramidal side-effects, age, disease duration or lifetime neuroleptic dose with echogenicity of the SN. Interestingly, we found a significant negative correlation of SN echogenicity with serum iron as well as serum transferrin levels. Conclusion: SN echogenicity apparently cannot be used as a biomarker for schizophrenic spectrum disorders or a predictor of neuroleptic-induced extrapyramidal side-effects in adolescents and young adults. Increased SN echogenicity, which is assumed to be an indicator of nigrostriatal injury, presumably evolves much later in the course of schizophrenic disorders. As our probands underwent examination only once in the course of their disease, we cannot draw conclusions regarding the development of SN echogenicity. Longitudinal studies are needed to shed more light on possible developmental changes in this regard. KW - Substantia nigra KW - Schizophrenie KW - Ultraschalldiagnostik KW - Juvenile Psychose KW - Extrapyramidales System KW - Substantia Nigra - Echogenität KW - Transkranieller Ultraschall KW - Adoleszenz KW - EPMS Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-231713 ER - TY - JOUR A1 - Jaite, Charlotte A1 - Bühren, Katharina A1 - Dahmen, Brigitte A1 - Dempfle, Astrid A1 - Becker, Katja A1 - Correll, Christoph U. A1 - Egberts, Karin M. A1 - Ehrlich, Stefan A1 - Fleischhaker, Christian A1 - von Gontard, Alexander A1 - Hahn, Freia A1 - Kolar, David A1 - Kaess, Michael A1 - Legenbauer, Tanja A1 - Renner, Tobias J. A1 - Schulze, Ulrike A1 - Sinzig, Judith A1 - Thomae, Ellen A1 - Weber, Linda A1 - Wessing, Ida A1 - Antony, Gisela A1 - Hebebrand, Johannes A1 - Föcker, Manuel A1 - Herpertz-Dahlmann, Beate T1 - Clinical Characteristics of Inpatients with Childhood vs. Adolescent Anorexia Nervosa JF - Nutrients N2 - We aimed to compare the clinical data at first presentation to inpatient treatment of children (<14 years) vs. adolescents (≥14 years) with anorexia nervosa (AN), focusing on duration of illness before hospital admission and body mass index (BMI) at admission and discharge, proven predictors of the outcomes of adolescent AN. Clinical data at first admission and at discharge in 289 inpatients with AN (children: n = 72; adolescents: n = 217) from a German multicenter, web-based registry for consecutively enrolled patients with childhood and adolescent AN were analyzed. Inclusion criteria were a maximum age of 18 years, first inpatient treatment due to AN, and a BMI <10th BMI percentile at admission. Compared to adolescents, children with AN had a shorter duration of illness before admission (median: 6.0 months vs. 8.0 months, p = 0.004) and higher BMI percentiles at admission (median: 0.7 vs. 0.2, p = 0.004) as well as at discharge (median: 19.3 vs. 15.1, p = 0.011). Thus, in our study, children with AN exhibited clinical characteristics that have been associated with better outcomes, including higher admission and discharge BMI percentile. Future studies should examine whether these factors are actually associated with positive long-term outcomes in children. KW - anorexia nervosa KW - children KW - adolescents KW - clinical characteristics KW - BMI KW - outcome Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193160 SN - 2072-6643 VL - 11 IS - 11 ER - TY - JOUR A1 - Jarick, I. A1 - Volckmar, A. L. A1 - Pütter, C. A1 - Pechlivanis, S. A1 - Nguyen, T. T. A1 - Dauvermann, M. R. A1 - Beck, S. A1 - Albayrak, Ö. A1 - Scherag, S. A1 - Gilsbach, S. A1 - Cichon, S. A1 - Hoffmann, P. A1 - Degenhardt, F. A1 - Nöthen, M. M. A1 - Schreiber, S. A1 - Wichmann, H. E. A1 - Jöckel, K. H. A1 - Heinrich, J. A1 - Tiesler, C. M. T. A1 - Faraone, S. V. A1 - Walitza, S. A1 - Sinzig, J. A1 - Freitag, C. A1 - Meyer, J. A1 - Herpertz-Dahlmann, B. A1 - Lehmkuhl, G. A1 - Renner, T. J. A1 - Warnke, A. A1 - Romanos, M. A1 - Lesch, K. P. A1 - Reif, A. A1 - Schimmelmann, B. G. A1 - Hebebrand, J. A1 - Scherag, A. A1 - Hinney, A. T1 - Genome-wide analysis of rare copy number variations reveals PARK2 as a candidate gene for attention-deficit/hyperactivity disorder JF - Molecular Psychiatry N2 - Attention-deficit/hyperactivity disorder (ADHD) is a common, highly heritable neurodevelopmental disorder. Genetic loci have not yet been identified by genome-wide association studies. Rare copy number variations (CNVs), such as chromosomal deletions or duplications, have been implicated in ADHD and other neurodevelopmental disorders. To identify rare (frequency ≤1%) CNVs that increase the risk of ADHD, we performed a whole-genome CNV analysis based on 489 young ADHD patients and 1285 adult population-based controls and identified one significantly associated CNV region. In tests for a global burden of large (>500 kb) rare CNVs, we observed a nonsignificant (P=0.271) 1.126-fold enriched rate of subjects carrying at least one such CNV in the group of ADHD cases. Locus-specific tests of association were used to assess if there were more rare CNVs in cases compared with controls. Detected CNVs, which were significantly enriched in the ADHD group, were validated by quantitative (q)PCR. Findings were replicated in an independent sample of 386 young patients with ADHD and 781 young population-based healthy controls. We identified rare CNVs within the parkinson protein 2 gene (PARK2) with a significantly higher prevalence in ADHD patients than in controls \((P=2.8 × 10^{-4})\) after empirical correction for genome-wide testing). In total, the PARK2 locus (chr 6: 162 659 756-162 767 019) harboured three deletions and nine duplications in the ADHD patients and two deletions and two duplications in the controls. By qPCR analysis, we validated 11 of the 12 CNVs in ADHD patients \((P=1.2 × 10^{-3})\) after empirical correction for genome-wide testing). In the replication sample, CNVs at the PARK2 locus were found in four additional ADHD patients and one additional control \((P=4.3 × 10^{-2})\). Our results suggest that copy number variants at the PARK2 locus contribute to the genetic susceptibility of ADHD. Mutations and CNVs in PARK2 are known to be associated with Parkinson disease. KW - children KW - ADHD KW - CNVs KW - GWAS KW - PARK2 Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121131 VL - 19 IS - 19 ER - TY - JOUR A1 - Kaiser, Anna A1 - Aggensteiner, Pascal-M. A1 - Holtmann, Martin A1 - Fallgatter, Andreas A1 - Romanos, Marcel A1 - Abenova, Karina A1 - Alm, Barbara A1 - Becker, Katja A1 - Döpfner, Manfred A1 - Ethofer, Thomas A1 - Freitag, Christine M. A1 - Geissler, Julia A1 - Hebebrand, Johannes A1 - Huss, Michael A1 - Jans, Thomas A1 - Jendreizik, Lea Teresa A1 - Ketter, Johanna A1 - Legenbauer, Tanja A1 - Philipsen, Alexandra A1 - Poustka, Luise A1 - Renner, Tobias A1 - Retz, Wolfgang A1 - Rösler, Michael A1 - Thome, Johannes A1 - Uebel-von Sandersleben, Henrik A1 - von Wirth, Elena A1 - Zinnow, Toivo A1 - Hohmann, Sarah A1 - Millenet, Sabina A1 - Holz, Nathalie E. A1 - Banaschewski, Tobias A1 - Brandeis, Daniel T1 - EEG data quality: determinants and impact in a multicenter study of children, adolescents, and adults with attention-deficit/hyperactivity disorder (ADHD) JF - Brain Sciences N2 - Electroencephalography (EEG) represents a widely established method for assessing altered and typically developing brain function. However, systematic studies on EEG data quality, its correlates, and consequences are scarce. To address this research gap, the current study focused on the percentage of artifact-free segments after standard EEG pre-processing as a data quality index. We analyzed participant-related and methodological influences, and validity by replicating landmark EEG effects. Further, effects of data quality on spectral power analyses beyond participant-related characteristics were explored. EEG data from a multicenter ADHD-cohort (age range 6 to 45 years), and a non-ADHD school-age control group were analyzed (n\(_{total}\) = 305). Resting-state data during eyes open, and eyes closed conditions, and task-related data during a cued Continuous Performance Task (CPT) were collected. After pre-processing, general linear models, and stepwise regression models were fitted to the data. We found that EEG data quality was strongly related to demographic characteristics, but not to methodological factors. We were able to replicate maturational, task, and ADHD effects reported in the EEG literature, establishing a link with EEG-landmark effects. Furthermore, we showed that poor data quality significantly increases spectral power beyond effects of maturation and symptom severity. Taken together, the current results indicate that with a careful design and systematic quality control, informative large-scale multicenter trials characterizing neurophysiological mechanisms in neurodevelopmental disorders across the lifespan are feasible. Nevertheless, results are restricted to the limitations reported. Future work will clarify predictive value. KW - electroencephalography (EEG) KW - data quality KW - attention-deficit/hyperactivity disorder (ADHD) KW - artifacts KW - multicenter study Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228788 SN - 2076-3425 VL - 11 IS - 2 ER - TY - THES A1 - Kipp, Ellen T1 - Therapeutisches Drug Monitoring von Clozapin und Olanzapin bei Kindern und Jugendlichen mit Erkrankungen aus dem schizophrenen Formenkreis T1 - Therapeutic drug monitoring in children and adolescents treated with clozapine and olanzapine for schizophrenic disorders N2 - Derzeit gibt es nur wenige Informationen zu konzentrationsabhängigen klinischen Effekten von Clozapin und Olanzapin in der Behandlung von Kindern und Jugendlichen mit schizophrenen Störungen. Es existieren keine altersspezifisch-definierte therapeutische Zielbereiche für die Höhe der Serumkonzentration in dieser Altersklasse. Das Ziel dieser retrospektiven, naturalistischen Studie ist die Untersuchung der Zusammenhänge zwischen Dosis, Serumkonzentration und klinischen Effekten (Therapieeffekt und unerwünschte Arzneimittelwirkungen) sowie die Untersuchung möglicher Einflussfaktoren darauf. Des Weiteren sollen Erkenntnisse zu therapeutischen Konzentrationsbereichen von Clozapin und Olanzapin bei Kindern und Jugendlichen gewonnen werden. Ausgewertet wurden multizentrische Daten von 32 (Clozapin) bzw. 17 (Olanzapin) Patienten, bei denen routinemäßig Therapeutisches Drug Monitoring im Zeitraum von Februar 2004 bis Dezember 2007 durchgeführt wurde. Die psychopathologische Befundeinschätzung erfolgte mittels der Clinical Global Impression Scale und der Brief Psychiatric Rating Scale, die der unerwünschten Arzneimittelwirkungen mithilfe der Dose Record and Treatment Emergent Symptom Scale bzw. der Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Bei beiden untersuchten Wirkstoffen zeigte sich eine signifikant positive Korrelation zwischen der (gewichtskorrigierten) Tagesdosis und der Serumkonzentration sowie eine hohe interindividuelle Variabilität der Serumkonzentrationen bei gleicher Dosierung. Als weiterer möglicher Einflussfaktor auf die Höhe der Serumkonzentration konnte in der Olanzapin-Stichprobe eine signifikante Assoziation zwischen dem Geschlecht und der Serumkonzentration nachgewiesen werden: Mädchen scheinen unter gleicher klinischer Dosierung höhere Serumkonzentrationen aufzubauen als Jungen. In beiden Stichproben gab es eine hohe Rate dokumentierter unerwünschter Arzneimittelwirkungen. Ein Zusammenhang zwischen der Höhe der Serumkonzentration und dem Auftreten unerwünschter Arzneimittelwirkungen ließ sich nicht nachweisen. In der Clozapin-Stichprobe zeigte sich ein signifikanter Zusammenhang zwischen der Serumkonzentration und dem Therapieeffekt: Im untersuchten Sample war der Therapieeffekt besser bei niedrigeren (< 350 ng/ml) Serumkonzentrationen. Zudem zeigte sich eine Tendenz zu einem niedrigeren unteren Schwellenwert für einen empfohlenen therapeutischen Bereich der Serumkonzentration verglichen mit dem Bereich der für Erwachsene definiert wurde. In der Olanzapin-Stichprobe ließ sich mit dem gewählten Studiendesign keine signifikante Korrelation zwischen der Serumkonzentration und dem Therapieeffekt nachweisen. Die Mehrheit der pädiatrischen Patienten hatte eine Serumkonzentration innerhalb des empfohlenen Zielbereichs für Erwachsene. Dieses Ergebnis könnte auf eine Übereinstimmung des zu empfehlenden Zielbereichs der Serumkonzentration von Olanzapin in beiden Altersklassen hinweisen. Aufgrund der Limitationen des naturalistischen Studiendesigns sind weitere Studien mit kontrolliertem Design und größerer Stichprobe notwendig, um die Ergebnisse zu replizieren. N2 - There is limited information on the concentration-dependent clinical effects of clozapine and olanzapine in the treatment of children and adolescents with schizophrenic disorders and age-specific therapeutic target ranges of serum concentrations in this age group are not defined yet. The aim of this retrospective, naturalistic study was to investigate the relationship between daily dose, serum concentrations and clinical outcome (positive therapeutic effects and adverse drug reactions) of clozapine and olanzapine in child and adolescents and finally, to investigate any factors influencing these relationships. Furthermore, it should be examined whether the recommended therapeutic concentration ranges for adults are also valid for children and adolescents. Data from 32 (clozapine) and 17 (olanzapine) patients were routinely collected between February 2004 and December 2007. Psychopathological findings were assessed using the Clinical Global Impression Scale and the Brief Psychiatric Rating Scale. Adverse drug reactions were assessed via the Dose Record and Treatment Emergent Symptom Scale and the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. For both substances investigated, a significant positive correlation was found between the (weight-corrected) daily dose and the serum concentration. Furthermore, a high interindividual variability of the serum concentrations at the same dose was observed. For olanzapine treated individuals, a significant association was found between gender and serum concentration: females were found to have higher serum concentrations than males at the same clinical dose. There was a high rate of documented adverse drug reactions for both substances. However, a correlation between the level of serum concentration and the occurrence of adverse drug reactions could not be demonstrated. In the clozapine sample, there was a significant correlation between the serum concentration and the therapeutic effect: In the investigated sample, the therapeutic effect was better at lower (<350 ng/ml) serum concentrations. In addition, results hint on a lower threshold for a recommended therapeutic range of serum concentration compared to the range defined for adults. In the olanzapine sample, with the selected study design a significant correlation between the serum concentration and the therapeutic effect was not shown. The majority of pediatric patients had serum concentrations within the recommended range for adults. This result hints on concordant recommended serum concentration ranges in both age groups. Due to the limitations of the naturalistic study design, further studies with controlled design and larger sample size are needed to verify and replicate the results. KW - Arzneimittelüberwachung KW - Schizophrenie KW - Clozapin KW - Olanzapin KW - Therapeutisches Drug Monitoring/therapeutic drug monitoring KW - Kinder und Jugendliche/children and adolescents KW - Clozapin/clozapine KW - Olanzapin/olanzapine Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-182699 ER - TY - THES A1 - Klampfl, Karin Maria T1 - Komorbidität bei Kindern und Jugendlichen mit einer Zwangsstörung T1 - Comorbidity in children and adolescents with obsessive-compulsive disorder N2 - Thema der vorliegenden Arbeit war die Erfassung und Beschreibung der psychiatrischen Komorbidität bei Kindern und Jugendlichen mit einer Zwangsstörung. An vier deutschen Universitätskliniken für Kinder- und Jugendpsychiatrie wurden konsekutiv 55 Kinder und Jugendliche mit juveniler Zwangsstörung im Hinblick auf Art und Ausprägung ihrer Zwangssymptomatik sowie hinsichtlich komorbid vorliegender psychiatrischer Störungen mit standardisierten Instrumenten untersucht. Die beschriebene Patientenstichprobe zeigte bezüglich klinischer und epidemiologischer Merkmale große Übereinstimmung mit den bisher epirisch gewonnenen Daten. Es konnte gezeigt werden, dass bei Kindern un Jugendlichen mit Zwangsstörung von einer hohen Zahl komorbider psychischer Störungen auszugehen ist, wobei Angststörungen, affektive Störungen und expansive Störungen (Hyperkinetisches Syndrom, Störung des Sozialverhaltens)am häufigsten zu diagnostizieren waren, gefolgt von Essstörungen und Tics. Die genaue Erhebung des Verteilungsmusters der komorbiden Störungen ist nicht nur von therapeutischer Relevanz, sondern kann auch einen Beitrag leisten, Untergruppen der juvenilen Zwangsstörung zu identifizieren und möglicherweise Rückschlüsse auf die Entstehung der Erkrankung zu ziehen. N2 - To analyze the kind and frequency of psychiatric comorbidity in children and adolescents with obsessive-compulsive disorder (OCD) 55 boys and girls were investigated with standardized instruments at four German university departments of child and adolescent psychiatry. Compared with the epidemiological and clinical features of peadiatric patients of former clinical studies our sample seemed representative. As a result psychiatric comorbidity was very common in both children and adolescents especially with anxiety-disorders, affective disorders and expansive behaviour disorders. Eating disorders and Tics also were found as comorbid conditions of juvenile OCD. The knowledge of these comorbid disorders is not only essential for the treatment it may also help to define subgroups of patients and thus to find out more of the origin and history of the illness. KW - Zwangsstörung KW - Kinder KW - Jugendliche KW - Komorbidität KW - obsessive-compulsive disorder KW - children KW - adolescents KW - psychiatric comorbidity Y1 - 2003 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-8139 ER - TY - THES A1 - Kneer, Katharina Johanna T1 - The association of three anxiety dimensions in children and adolescents: their influence on the brain and malleability by a prevention program T1 - Der Zusammenhang dreier Angstdimensionen bei Kindern und Jugendlichen: ihr Einfluss auf das Gehirn und ihre Veränderbarkeit durch ein Präventionsprogramm N2 - Anxiety disorders are the most prevalent group of neuropsychiatric disorders and go along with high personal suffering. They often arise during childhood and show a progression across the life span, thus making this age a specific vulnerable period during development. Still most research about these disorders is done in adults. In light of this, it seems of utmost importance to identify predictive factors of anxiety disorders in children and adolescents. Temperament or personality traits have been proclaimed as risk markers for the development of subsequent anxiety disorders, but their exact interplay is not clear. In this dissertation an effort is made to contribute to the understanding of how risk markers of early temperamental traits, in this case Trait Anxiety, Anxiety Sensitivity and Separation Anxiety are interplaying. While Trait Anxiety is regarded as a more general tendency to react anxiously to threatening situations or stimuli (Unnewehr, Joormann, Schneider, & Margraf, 1992), Anxiety Sensitivity is the tendency to react with fear to one’s own anxious sensations (Allan et al., 2014; S. Reiss, Peterson, Gursky, & McNally, 1986), and Separation Anxiety is referring to the extent to which the child is avoiding certain situations because of the fear of being separated from primary care givers (In-Albon & Schneider, 2011). In addition, it will be addressed how these measurements are associated with negative life events, as well as brain functioning and if they are malleable by a prevention program in children and adolescents. In study 1 the aim was to extend the knowledge about the interrelations of this anxiety dimensions and negative life events. Results indicated positive correlations of all three anxiety traits as well as with negative life events. Thus, a close connection of all three anxiety measures as well as with negative life events could be indicated. The closest association was found between Anxiety Sensitivity and Trait Anxiety and between Separation Anxiety and Anxiety Sensitivity. Furthermore, negative life events functioned as mediator between Anxiety Sensitivity and Trait Anxiety, indicating that a part of the association was explained by negative life events. In study 2 we extended the findings from study 1 with neurobiological parameters and examined the influence of anxiety traits on emotional brain activation by administering the “emotional face matching task”. This task activated bilateral prefrontal regions as well as both hippocampi and the right amygdala. Further analyses indicated dimension-specific brain activations: Trait Anxiety was associated with a hyperactivation of the left inferior frontal gyrus (IFG) and Separation Anxiety with a lower activation bilaterally in the IFG and the right middle frontal gyrus (MFG). Furthermore, the association between Separation Anxiety and Anxiety Sensitivity was moderated by bi-hemispheric Separation-Anxiety-related IFG activation. Thus, we could identify distinct brain activation patterns for the anxiety dimensions (Trait Anxiety and Separation Anxiety) and their associations (Separation Anxiety and Anxiety Sensitivity). The aim of study 3 was to probe the selective malleability of the anxiety dimensions via a prevention program in an at-risk population. We could identify a reduction of all three anxiety traits from pre- to post-prevention-assessment and that this effect was significant in Anxiety Sensitivity and Trait Anxiety scores. Furthermore, we found that pre-intervention Separation Anxiety and Anxiety Sensitivity post-intervention were associated. In addition, pre-interventive scores were correlated with the intervention-induced change within the measure (i.e., the higher the score before the intervention the higher the prevention-induced change) and pre-intervention Anxiety Sensitivity correlated with the change in Separation Anxiety scores. All relations, seemed to be direct, as mediation/moderation analyses with negative life events did not reveal any significant effect. These results are very promising, because research about anxiety prevention in children and adolescents is still rare and our results are indicating that cognitive-behavioural-therapy based prevention is gilding significant results in an indicated sample even when samples sizes are small like in our study. In sum the present findings hint towards distinct mechanisms underlying the three different anxiety dimensions on a phenomenological and neurobiological level, though they are highly overlapping (Higa-McMillan, Francis, Rith-Najarian, & Chorpita, 2016; Taylor, 1998). Furthermore, the closest associations were found between Anxiety Sensitivity and Trait Anxiety, as well as between Separation Anxiety and Anxiety Sensitivity. Specifically, we were able to find a neuronal manifestation of the association between Separation Anxiety and Anxiety Sensitivity (Separation Anxiety-specific IFG activation) and a predictive potential on prevention influence. The results of these studies lead to a better understanding of the etiology of anxiety disorders and the interplay between different anxiety-related temperamental traits and could lead to further valuable knowledge about the intervention as well as further prevention strategies. N2 - Angststörungen sind die am häufigsten auftretende Gruppe neuropsychiatrischer Erkrankungen und führen in vielen Fällen zu großem Leid. Sie beginnen häufig in der Kindheit und Spontanremissionen sind selten, im Gegenteil - die Erkrankungen verschlimmern sich häufig und führen zu weiteren psychischen Erkrankungen. Dabei stellt die Kindheit eine Lebensphase mit besonderer Vulnerabilität für die Entwicklung von Angsterkrankungen dar. Trotzdem werden die meisten Studien zu Angststörungen weiterhin mit Erwachsenen durchgeführt. Vor diesem Hintergrund scheint es von größter Bedeutung, prädiktive Faktoren für Angststörungen bei Kindern und Jugendlichen zu identifizieren. Temperament- oder Persönlichkeitsmerkmale werden als Risikomarker für Angststörungen gesehen. Dabei ist das genaue Zusammenspiel dieser Risikomarker im Kindes- und Jugendalter nicht klar. Diese Dissertation leistet dabei einen Beitrag zum Verständnis des Zusammenspiels der Risikomarker Trait-Angst, Angstsensitivität und Trennungsangst. Während Trait-Angst als eine eher allgemeinere Tendenz angesehen wird, ängstlich auf bedrohliche Situationen oder Reize zu reagieren (Unnewehr et al., 1992), ist Angstsensitivität die Tendenz, mit Angst auf die eigenen potentiell angst-assoziierten Empfindungen zu reagieren (Allan et al., 2014; S. Reiss et al., 1986). Trennungsangst bezieht sich auf das Ausmaß, in dem das Kind bestimmt Situationen vermeidet, weil es befürchtet von Primärbezugspersonen getrennt zu werden (In-Albon & Schneider, 2011). Darüber hinaus befasst sich diese Dissertation damit, wie diese drei Angstmaße mit negativen Lebensereignissen und Gehirnaktivierung zusammenhängen und evaluiert deren Veränderbarkeit durch ein indiziertes Präventionsprogram. Zu diesem Zweck wurden drei Studien durchgeführt. In Studie 1 war das Ziel, das Wissen, um die Wechselbeziehungen dieser Angstmaße und negativer Lebensereignisse zu erweitern. Die Ergebnisse zeigten enge Zusammenhänge zwischen den drei Angstmaßen und ebenso mit der Anzahl negativer Lebensereignissen. Darüber hinaus fungierten negative Lebensereignisse als Mediator zwischen Angstsensitivität und Trait-Angst, was darauf hinweist, dass ein Teil des Zusammenhangs dieser beiden Angstmaße durch negative Lebensereignisse erklärt wird. In Studie 2 erweiterten wir die Ergebnisse aus Studie 1 um ein neurobiologisches Maß und untersuchten den Einfluss der Angstmaße auf Hirnaktivierung während emotionaler Verarbeitung mittels der Durchführung des „emotional face matching task“. Die Analyse zeigte eine Aktivierung während der Aufgabe in bilateralen präfrontalen Regionen sowie beiden Hippocampi und der rechten Amygdala. Angstspezifische Aktivierungen zeigten eine Trait-Angst-spezifische Hyperaktivierung im linken gyrus frontalis inferior (IFG) und eine Trennungsangst-spezifische Hypoaktivierung in beiden IFG und dem rechten gyrus frontalis medius. Darüber hinaus wurde der Zusammenhang zwischen Trennungsangst und Angstsensitivität durch bi-hemisphärische Trennungsangst-spezifische IFG Aktivierung moderiert. Wir konnten also Hirnregionen identifizieren, die spezifisch mit den Angstmaßen assoziiert waren (Trait-Angst und Trennungsangst) und auch deren Verbindung moderierten (Trennungsangst und Angstsensitivität). Ziel der Studie 3 war es, die Veränderbarkeit der Angstmaße anhand eines Präventionsprogramms in einer Risikopopulation zu untersuchen. Wir konnten eine Verringerung aller drei Angstmaße durch die Prävention feststellen und dieser Effekt war für Angstsensitivität und Trait-Angst statistisch signifikant. Darüber hinaus konnten wir zeigen, dass die Trennungsangst vor der Prävention signifikant mit der Angstsensitivität nach der Prävention korrelierte. Zusätzlich sagte das Ausmaß der Angstmaße vor der Prävention die durch die Intervention induzierten Veränderung innerhalb eines Maßes signifikant voraus (Je höher die Werte vor der Intervention, desto höher die präventionsinduzierte Änderung), zudem vermochte Angstsensitivität vor der Intervention Änderung der Trennungsangstwerte zu prognostizierten. Alle gefunden Zusammenhänge schienen darüber hinaus direkt zu sein, da Mediations- / Moderationsanalysen mit negativen Lebensereignissen keinen signifikanten Effekt zeigten. Diese Ergebnisse sind sehr vielversprechend, da es nur wenig Forschung zur Angstprävention bei Kindern und Jugendlichen gibt und unsere Ergebnisse darauf hinweisen das Präventionsprogramme, welche auf Kognitiv-verhaltenstherapeutischen Elementen beruhen in einer indizierten Population gute Effekte erzielen können, selbst wenn es sich, wie in unserem Fall, um eine kleine Stichprobengröße handelt. Zusammenfassend deuten die vorliegenden Ergebnisse auf unterschiedliche Mechanismen hin, die den drei verschiedenen Angstmaßen auf phänomenologischer und neurobiologischer Ebene zugrunde liegen. Darüber hinaus wurden enge Assoziationen zwischen Angstsensitivität und Trait-Angst sowie Trennungsangst und Angstsensitivität gefunden. Insbesondere konnten wir eine neuronale Manifestation des Zusammenhangs zwischen Trennungsangst und Angstsensitivität (Trennungangstspezifische IFG-Aktivierung) und ein Vorhersagepotential für den Einfluss der Prävention finden. Die Resultate der beschriebenen Studien tragen zu einem besseren Verständnis der Ätiologie von Angststörungen und dem Zusammenspiel verschiedener angstspezifischer Temperamentmerkmale bei, und können zu weiteren wertvollen Erkenntnissen über Interventions- sowie Präventionsstrategien führen. KW - Prävention KW - Angst KW - Kind KW - Jugend KW - Angsterkrankungen KW - Kindheit und Jugend KW - Angst als Eigenschaft Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-257468 ER - TY - JOUR A1 - Kolar, David R. A1 - Hammerle, Florian A1 - Jenetzky, Ekkehart A1 - Huss, Michael A1 - Bürger, Arne T1 - Aversive tension in female adolescents with Anorexia Nervosa: a controlled ecological momentary assessment using smartphones JF - BMC Psychiatry N2 - Background Current models of Anorexia Nervosa (AN) emphasize the role of emotion regulation. Aversive tension, described as a state of intense arousal and negative valence, is considered to be a link between emotional events and disordered eating. Recent research focused only on adult patients, and mainly general emotion regulation traits were studied. However, the momentary occurrence of aversive tension, particularly in adolescents with AN, has not been previously studied. Method 20 female adolescents with AN in outpatient treatment and 20 healthy adolescents aged 12 to 19 years participated in an ecological momentary assessment using their smartphones. Current states of aversive tension and events were assessed hourly for two consecutive weekdays. Mean and maximum values of aversive tension were compared. Multilevel analyses were computed to test the influence of time and reported events on aversive tension. The effect of reported events on subsequent changes of aversive tension in patients with AN were additionally tested in a multilevel model. Results AN patients showed higher mean and maximum levels of aversive tension. In a multilevel model, reported food intake was associated with higher levels of aversive tension in the AN group, whereas reported school or sport-related events were not linked to specific states of aversive tension. After food intake, subsequent increases of aversive tension were diminished and decreases of aversive tension were induced in adolescents with AN. Conclusions Aversive tension may play a substantial role in the psychopathology of AN, particular in relation with food intake. Therefore, treatment should consider aversive tension as a possible intervening variable during refeeding. Our findings encourage further research on aversive tension and its link to disordered eating. KW - Anorexia nervosa KW - Adolescence KW - Aversive tension KW - Ecological momentary assessment KW - Emotion regulation KW - Eating disorder KW - Smartphones Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164720 VL - 16 IS - 97 ER - TY - JOUR A1 - Kuhlmann, S.M. A1 - Huss, M. A1 - Bürger, A. A1 - Hammerle, F. T1 - Coping with stress in medical students: results of a randomized controlled trial using a mindfulness-based stress prevention training (MediMind) in Germany JF - BMC Medical Education N2 - Background High prevalence rates of psychological distress in medical training and later professional life indicate a need for prevention. Different types of intervention were shown to have good effects, but little is known about the relative efficacy of different types of stress management interventions, and methodological limitations have been reported. In order to overcome some of these limitations, the present study aimed at evaluating the effect of a specifically developed mindfulness-based stress prevention training for medical students (MediMind) on measures of distress, coping and psychological morbidity. Methods We report on a prospective randomized controlled trial with three study conditions: experimental treatment (MediMind), standard treatment (Autogenic Training) and a control group without treatment. The sample consisted of medical or dental students in the second or eighth semester. They completed self-report questionnaires at baseline, after the training and at one year follow-up. Distress (Trier Inventory for the Assessment of Chronic Stress, TICS) was assessed as the primary outcome and coping (Brief COPE) as a co-primary outcome. Effects on the psychological morbidity (Brief Symptom Inventory, BSI) as a secondary outcome were expected one year after the trainings. Results Initially, N = 183 students were randomly allocated to the study groups. At one year follow-up N = 80 could be included into the per-protocol analysis: MediMind (n =31), Autogenic Training (n = 32) and control group (n = 17). A selective drop-out for students who suffered more often from psychological symptoms was detected (p = .020). MANCOVA’s on TICS and Brief COPE revealed no significant interaction effects. On the BSI, a significant overall interaction effect became apparent (p = .002, η2partial = .382), but post hoc analyses were not significant. Means of the Global Severity Index (BSI) indicated that MediMind may contribute to a decrease in psychological morbidity. Conclusion Due to the high and selective dropout rates, the results cannot be generalized and further research is necessary. Since the participation rate of the trainings was high, a need for further prevention programs is indicated. The study gives important suggestions on further implementation and evaluation of stress prevention in medical schools. KW - Medical students KW - Distress KW - Stress KW - Stress prevention KW - Mindfulness Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164593 VL - 16 ER - TY - JOUR A1 - Kuhn, Manuel A1 - Scharfenort, Robert A1 - Schümann, Dirk A1 - Schiele, Miriam A. A1 - Münsterkötter, Anna L. A1 - Deckert, Jürgen A1 - Domschke, Katharina A1 - Haaker, Jan A1 - Kalisch, Raffael A1 - Pauli, Paul A1 - Reif, Andreas A1 - Romanos, Marcel A1 - Zwanzger, Peter A1 - Lonsdorf, Tina B. T1 - Mismatch or allostatic load? Timing of life adversity differentially shapes gray matter volume and anxious temperament JF - Social Cognitive and Affective Neuroscience N2 - Traditionally, adversity was defined as the accumulation of environmental events (allostatic load). Recently however, a mismatch between the early and the later (adult) environment (mismatch) has been hypothesized to be critical for disease development, a hypothesis that has not yet been tested explicitly in humans. We explored the impact of timing of life adversity (childhood and past year) on anxiety and depression levels (N = 833) and brain morphology (N = 129). Both remote (childhood) and proximal (recent) adversities were differentially mirrored in morphometric changes in areas critically involved in emotional processing (i.e. amygdala/hippocampus, dorsal anterior cingulate cortex, respectively). The effect of adversity on affect acted in an additive way with no evidence for interactions (mismatch). Structural equation modeling demonstrated a direct effect of adversity on morphometric estimates and anxiety/depression without evidence of brain morphology functioning as a mediator. Our results highlight that adversity manifests as pronounced changes in brain morphometric and affective temperament even though these seem to represent distinct mechanistic pathways. A major goal of future studies should be to define critical time periods for the impact of adversity and strategies for intervening to prevent or reverse the effects of adverse childhood life experiences. KW - VBM KW - childhood maltreatment KW - adversity KW - stressful life events KW - mismatch KW - allostatic load Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-189645 VL - 11 IS - 4 ER - TY - THES A1 - Kämpf, Anne Kristina T1 - Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder? T1 - Zytogenetische Veränderungen durch Methylphenidat bei Kindern mit ADHS? N2 - MPH wird seit über 50 Jahren zur Therapie des ADHS eingesetzt. Gerade in den letzten Jahren wurde deutlich, dass der Einsatz ohne fundierte Kenntnis über mögliche Langzeit-effekte erfolgte, da zum Zeitpunkt der Zulassung aufgrund der begrenzten technischen Möglichkeiten weniger strenge und weniger umfassende Einschränkungen beachtet wer-den mussten (Walitza, Werner et al. 2007). Da in den letzten Jahren die Anzahl der verschrieben Tagesdosen MPH sprunghaft anstiegen, ist es wichtig, auch die langfristigen Nebenwirkungen von MPH zu untersuchen (Janhsen 2007). Eine Studie von El-Zein et al. von 2005 brachte die Frage auf, ob MPH eventuell Genomschäden hervorrufe. Bei 11 von 12 untersuchten Kindern wurde unter der Therapie mit MPH um das 2,4fache erhöhte Mikrokernfrequenzen gefunden (El-Zein, Abdel-Rahman et al. 2005). Dies beunruhig-te vor allem im Hinblick auf das mit erhöhten Mikrokernfrequenzen korrelierte erhöhte Karzinomrisiko. Eine daraufhin von Walitza et al. durchgeführte Studie, die ebenfalls Mikrokernfrequenzen in peripheren Blutzellen untersuchte (Walitza, Werner et al. 2007), konnte keine Hinweise auf eine Genomschädigung durch MPH erbringen. Zahlreiche weitere Untersuchungen zur potentiellen Genomschädigung durch MPH konnten die Ergebnisse durch in vivo- oder in vitro-Studien nicht bestätigen und kritisierten die ge-ringe Stichprobengröße sowie mangelnde Transparenz der Arbeit von El-Zein (Preston, Kollins et al. 2005; El-Zein, Hay et al. 2006; Holtmann, Kaina et al. 2006; Suter, Martus et al. 2006). Da jedoch keine weitere Studie sich konkret mit zytogenetischen Effekten in peripheren Blutzellen befasste, soll die vorliegende Arbeit dazu dienen, den Verdacht einer Genomschädigung endgültig auszuräumen (Walitza, Kampf et al. 2009). Dazu wurde eine größere Gruppe von Kindern eingeschlossen, sowie Untersuchungen zu verschiedenen Zeitpunkten während der MPH-Einnahme, bis hin zu Untersuchungen nach einem Zeitraum von 12 Monaten der MPH- Einnahme, durchgeführt. Mit Hilfe eines Mikrokerntestes wurden in der vorliegenden Studie versucht, DNS-Schäden an periphe-ren Lymphozyten zu bestimmen, um daraus auf ein potentiell erhöhtes Krebsrisiko schließen zu können. Im Vergleich mit einer gesunden Kontrollgruppe waren die Werte von ADHS-Kindern ohne MPH-Therapie sowie nach 3 und 12 Monaten MPH-Therapie zwar signifikant er-höht, diese gesunde Kontrollgruppe wies jedoch im Vergleich mit internationalen Refe-renzwerten eine extrem niedrige Mikrokernfrequenz auf, so dass davon ausgegangen werden muss, dass diese Vergleiche nur begrenzte Aussagekraft haben. In keiner der verschiedenen mit MPH therapierten Gruppen konnten über die Dauer der Einnahme eine signifikant Erhöhung der Mikrokernfrequenzen im Vergleich zu den Werten vor Einnahmebeginn nachgewiesen werden, was den Schluss zulässt, dass eine Therapie mit Methylphenidat in therapieüblichen Dosen bei Kindern das Erbgut nicht zu schädigen scheint. Dieses Ergebnis bestätigen inzwischen auch weitere Studien. Der Mikrokerntest erfasst Genomschäden, nicht jedoch etwaige tumorpromovierende Eigenschaften des verabreichten Medikaments. Damit ist unklar, ob MPH auf andere Art als über eine Schädigung des Genoms das Karzinomrisiko erhöhen könnte. Erste epidemiologische Studien sehen jedoch keinen Hinweis auf eine wie auch immer entstandene erhöhte Karzinominzidenz unter der Therapie mit MPH (Selby, Friedman et al. 1989; Oestreicher, Friedman et al. 2007). Hier scheinen jedoch weitere epidemiologische Studien, die mög-lichst große Zeitspannen umfassen, nötig zu sein N2 - Attention-deficit/hyperactivity disorder (ADHD) is the most frequent psychiatric disorder in children and adolescents and is often treated with methylphenidate (MPH), resulting in MPH exposure in more than 1% of all children in many countries. A 2005 report on cytogenetic effects in peripheral lymphocytes from 12 ADHD children treated for 3 months with MPH raised questions about its genetic toxicity and potential carcinogenicity. A healthy control group (23 individuals), a chronically MPH-treated (>12 months) group (21 patients), and a drug naïve group of ADHD-affected children (26 patients), which was analyzed again after 3 months (17 patients) and 6 months (11 patients), provided samples for analysis of micronucleated lymphocytes. No significant alteration in genomic damage as seen as micronucleus frequency in peripheral lypmphocytes was detected after MPH treatment. No indication for genomic damage induced by MPH was obtained in this study. Ongoing studies in the USA, as well as continuation of recently published epidemiological cancer incidence analysis should provide additional reassurance for MPH-treated ADHD patients. KW - Methylphenidat KW - Aufmerksamkeits-Defizit-Syndrom KW - Kleinkern KW - micronucleus assay KW - cytogenetic effects KW - mutagenicity Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-77652 ER - TY - JOUR A1 - Lechermeier, Carina G. A1 - Zimmer, Frederic A1 - Lüffe, Teresa M. A1 - Lesch, Klaus-Peter A1 - Romanos, Marcel A1 - Lillesaar, Christina A1 - Drepper, Carsten T1 - Transcript analysis of zebrafish GLUT3 genes, slc2a3a and slc2a3b, define overlapping as well as distinct expression domains in the zebrafish (Danio rerio) central nervous system JF - Frontiers in Molecular Neuroscience N2 - The transport of glucose across the cell plasma membrane is vital to most mammalian cells. The glucose transporter (GLUT; also called SLC2A) family of transmembrane solute carriers is responsible for this function in vivo. GLUT proteins encompass 14 different isoforms in humans with different cell type-specific expression patterns and activities. Central to glucose utilization and delivery in the brain is the neuronally expressed GLUT3. Recent research has shown an involvement of GLUT3 genetic variation or altered expression in several different brain disorders, including Huntington’s and Alzheimer’s diseases. Furthermore, GLUT3 was identified as a potential risk gene for multiple psychiatric disorders. To study the role of GLUT3 in brain function and disease a more detailed knowledge of its expression in model organisms is needed. Zebrafish (Danio rerio) has in recent years gained popularity as a model organism for brain research and is now well-established for modeling psychiatric disorders. Here, we have analyzed the sequence of GLUT3 orthologs and identified two paralogous genes in the zebrafish, slc2a3a and slc2a3b. Interestingly, the Glut3b protein sequence contains a unique stretch of amino acids, which may be important for functional regulation. The slc2a3a transcript is detectable in the central nervous system including distinct cellular populations in telencephalon, diencephalon, mesencephalon and rhombencephalon at embryonic and larval stages. Conversely, the slc2a3b transcript shows a rather diffuse expression pattern at different embryonic stages and brain regions. Expression of slc2a3a is maintained in the adult brain and is found in the telencephalon, diencephalon, mesencephalon, cerebellum and medulla oblongata. The slc2a3b transcripts are present in overlapping as well as distinct regions compared to slc2a3a. Double in situ hybridizations were used to demonstrate that slc2a3a is expressed by some GABAergic neurons at embryonic stages. This detailed description of zebrafish slc2a3a and slc2a3b expression at developmental and adult stages paves the way for further investigations of normal GLUT3 function and its role in brain disorders. KW - glucose transporter KW - nervous system KW - brain disorders KW - psychiatric disorders KW - brain development KW - GABA KW - GAD1 Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201797 VL - 12 IS - 199 ER -